IVD Medical Announces 2022 Interim Results ACN Newswire

IVD Medical Announces 2022 Interim Results

HONG KONG, Aug 22, 2022 - (ACN Newswire via SEAPRWire.com) - IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period"). During the Period, although hospitals were closed and other quarantine and social distancing measures were put in place in mainland China due to the COVID-19 pandemic, which resulted in a temporary decrease in end customers' demand for IVD product. With the help of its competitive and diverse product portfolio, extensive distribution network and growing maintenance services business, the Group still recorded revenue of RMB1,176,557,000 (six months ended 30 June 2021: RMB1,186,791,000), a similar level to that in the same period last year. Gross profit increased by 11% year-on-year to RMB266,423,000 and gross profit margin was up 2.4 percentage points year-on-year to 22.6%. The increases were mainly attributable to the decrease in purchase price of IVD analysers and the increase in maintenance services revenue with relatively stable maintenance cost. Driven by rising profit margin, the Group's adjusted profit for the period amounted to RMB96,773,000, 6.7% more year-on-year. The Board resolved to declare the payment of an interim dividend of HK2.729 cents per share for the six months ended 30 June 2022. Mr. Ho Kuk Sing, Chairman of IVD Medical, said, "In 2022, although the business environment of the medical industry has been tough under the pandemic, we have worked hard to overcome challenges and optimize our business operations. For distribution business, we signed a five-year exclusive distribution agreement with Sysmex in April this year. We have expanded our distribution network and hospital coverage to consolidate our position in the industry. Furthermore, our maintenance services business has been developing steadily with the notable growth in revenue, gross profit and gross profit margin. Looking ahead, we are prepared to capture potential growth opportunities in the industry and committed to bring better and long-term returns to shareholders."Business ReviewThe Group is a leading distributor of IVD products in the People's Republic of China ("PRC"). It has also engaged in research, development, manufacturing and sales of its self-branded IVD products.Distribution BusinessThe distribution of IVD products forms the cornerstone of the Group's business. It primarily involves the trading of IVD analysers, reagents and other consumables to customers such as distributors, hospitals and healthcare institutions and logistics providers. During the Period, revenue from this segment was RMB1,097,468,000, with gross profit up 3.1% to RMB216,907,000.Through years of operation, the Group has established an expansive distribution network across 29 provinces, municipalities and autonomous regions in the PRC with an extensive hospital coverage. As of 30 June 2022, the Group has 204 direct customers, including hospitals and healthcare institutions, and 908 distributors in its established distribution network. The Group distributes IVD products through its wholly-owned subsidiary Vastec Medical Limited ("Vastec"). Vastec has been the sole nationwide distributor of Sysmex haemostasis products with exclusive distribution rights in the PRC since 1997, and also procures a diversified portfolio of IVD products from other leading international brands for distribution in the PRC. On 1 April 2022, Vastec signed a five-year distribution agreement of Sysmex haemostasis products with exclusive distribution rights which is valid till 31 March 2027. The agreement has helped to strengthen the long-term and quality cooperation between Vastec and Sysmex. Moreover, the Group has provided four Thrombotic Markers(2) products manufactured by Sysmex to the market. These products adopt highly sensitive chemiluminescence technology, which may facilitate early diagnosis of thrombosis and fibrinolysis. The Group also provides solution services to clinical laboratories of hospitals, as such, it has enabled the Group to establish and maintain direct relationships with local medical practitioners so as to keep the Group close to the frontline of the medical practice and the demand of IVD products. In the first half of 2022, the Group provided solution services to eight Class III hospitals in the PRC.Maintenance ServicesThe Group provides maintenance services to end customers of Sysmex' haemostasis analysers. In 2017, Vastec entered into a maintenance services agreement with Sysmex to provide maintenance services to haemostasis analysers procured by its end customers. The maintenance services provided by Vastec generally include maintenance and repair services, installation services and end customer trainings. And, it primarily provides its maintenance services to hospitals and healthcare institutions. During the Reporting Period, the maintenance services business has been sustainably and steadily developing, with revenue amounted to RMB77,286,000, up by 27.8% against the same period last year. Gross profit of this segment increased by 70.2% to RMB48,388,000 and gross profit margin was up 15.6 percentage points to 62.6% for the period. Self-Branded Products BusinessThe Group has also engaged in the research and development, manufacturing and sales of IVD analysers and reagents under its own brand. The Group's self-branded IVD reagents were manufactured by Suzhou DiagVita Biotechnology Co., Ltd. and Bazoe Medical Co., Ltd., and the Group's IVD analysers were produced by its equipment manufacturers, IVD Medical Equipment (Shanghai) Ltd. and Langmai Biotechnology (Shandong) Co., Ltd. In addition, the Group distributes self-developed IVD products under its own brand which includes IVD analysers and reagents primarily under the IVD testing category of Point-of-care testing ("POCT"), mass spectrometry and microbiology.OutlookIn the future, the Group will continue to consolidate its leading position in the IVD industry in the PRC. To realise this goal, the Group aims to continuously expand its product portfolio by diversifying product categories, increasing brand coverage, and further expanding the breadth of its distribution network and hospital coverage. In this way, the Group will be able to capitalise on the high growth potential in the IVD market.Furthermore, the Group will continue to develop its distribution business by enhancing its capacity in providing solution services. By being the general supplier of the clinical laboratory department in such hospitals, the Group participates in the design of laboratory layout, provides centralised procurement of IVD products, conducts real-time inventory monitoring and provides other after-sale services to clinical laboratories. It also plans to hire more sales personnel to promote and market its solution services and to stock sufficient IVD products of various brands to strengthen its advantages in centralized procurement. To enhance brand awareness, it will continuously participate in national and local IVD symposiums, as well as academic conferences. In addition, the Group believes that strong research and development ("R&D") capabilities are critical to securing its future development and sustainable growth. It will therefore invest more resources to further improve its R&D capabilities by acquiring equipment, instruments and hiring experts in the relevant fields. The Group will also engage in research projects to further develop self-branded IVD products that holding promising market potential. The Group is keen to further strengthen product quality management and optimize the performance and applicability of self-developed products to improve market competitiveness.Mr. Leung King Sun, Chief Operation Officer of the Group, said, "Given the growing medical expenses per capita and government support to the industry pursuing technological development, the Group remains optimistic about the development prospects of the medical market in the PRC, particularly the medical equipment market. Priding competitiveness, a diverse product portfolio, an expansive distribution network and extensive hospital coverage, we are confident of seizing every potential opportunity. Meanwhile, we will continue to strengthen solution services for hospitals and enhance R&D capabilities for our own brands, and ultimately consolidate our leading position in the industry."About IVD Medical Holding LimitedIVD Medical Holding Limited ("IVD Medical" or the "Group") is a leading distributor of IVD products in the PRC. Its key subsidiaries include Vastec Medical Limited, Dacheng Medical Equipments (Shanghai) Co., Ltd., IVD China Limited, Suzhou DiagVita Biotechnology Co., Ltd., Langmai Biotechnology (Shandong) Co., Ltd and Bazoe Medical Co., Ltd. The Group's distribution network covers 29 provinces, municipalities and autonomous regions across the PRC. It is the sole national distributor of Sysmex' haemostasis products in the PRC and provides maintenance services to its end customers. It also engages in the R&D, manufacturing and sales of self-branded IVD analysers and reagents and provides solution services to clinical laboratories of hospitals for centralised procurement.Notes:(1) IVD, "In Vitro Diagnostic", which encompasses tests done on samples such as blood or tissue taken from the human body(2) 4 Thrombotic Markers refer to: 1)TAT: Thrombin-antithrombin complex, 2)PIC: Plasmin - a2-plasmin inhibitor complex, 3)TM: Thrombomodulin, 4)t-PAI-C: Tissue plasminogen activator/plasminogen activator inhibitor-1 complex.Media Enquiries:Strategic Financial Relations LimitedHeidi So Tel: (852) 2114 4320 Email: heidi.so@sprg.com.hkYan Li Tel: (852) 2864 4826 Email: yan.li@sprg.com.hkCherry Chen Tel: (852) 2114 4309 Email: cherry.chen@sprg.com.hkFax: (852) 2527 1196 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
ALTAVA Enters into Partnership with Hyundai Department Store SeaPRwire

ALTAVA Enters into Partnership with Hyundai Department Store

Hyundai Department Store Set to Strengthen Its Web3 Presence through the MOU with ALTAVA Seoul, Korea, August 09, 2022 – (SEAPRWire) – ALTAVA Group, the leading luxury fashion metaverse, signs an MOU with Hyundai Department Store, one of South Korea’s three largest department store chains, in order to strengthen their Web3 presence. Hyundai was the first department store in Korea to launch a digital wallet when the company announced H.NFT wallet earlier this year. H.NFT, can be accessed through Hyundai Department Store Group’s H.Point app, a membership service offered by all subsidiaries in the group. “ALTAVA is one of the leaders when it comes to helping leading luxury brands to connect to Web3. This cooperation will strengthen the utility and add premium value for our H.NFT wallet and its users,” said a representative from Hyundai Department Store. “Hyundai Department Store plans to issue NFTs containing information on promotional events and VIP lounge access, and collaborate with artists to create tokenized digital art. We are excited to work closely with them to bring additional content and services to their customers,” said Andy Ku, ALTAVA Group CEO/Co-Founder. About ALTAVA Group ALTAVA Group is a Singapore-based company with offices in Seoul, Ho Chi Minh City, London, and Paris. ALTAVA is the luxury fashion metaverse that enable users to discover, interact, and express themselves through hi-fidelity avatar. The Company operates WOY (World of You), a meter verse that provides omni-platform experiential solution which seamlessly connect consumers to real-world and virtual world for high-end luxury brands and discerning partners. Link to ALTAVA Social Media/ Website Announcement Telegram: https://t.me/altavaofficial Telegram Chat: https://t.me/altavachat Discord: discord.gg/altava Twitter: twitter.com/altavagroup Medium: medium.com/@altavagroup Facebook: https://www.facebook.com/altavagroup Linkedin: https://www.linkedin.com/company/altava Instagram: https://www.instagram.com/altavagroup/ Japan Telegram: https://t.me/altavajapan Japan Twitter: https://twitter.com/altavagroupjp PR/Media Contact Brand: ALTAVA Name of Contact Person: Oh Thongsrinoon Email: media@altava.com Company Headquarter: 6 Eu Tong Sen Street #11-1OU, The Central, Singpore 059817 Website: https://altava.com/ SOURCE: ALTAVA The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
Swang Chai Chuan Limited Announces Details of Proposed Listing on the Main Board of The Stock Exchange of Hong Kong Limited ACN Newswire

Swang Chai Chuan Limited Announces Details of Proposed Listing on the Main Board of The Stock Exchange of Hong Kong Limited

HONG KONG, Aug 8, 2022 - (ACN Newswire via SEAPRWire.com) - Swang Chai Chuan Limited ("Swang Chai Chuan" or the "Group"), an established distributor of Food & Beverage ("F&B") and other products for recognised international and domestic third-party brands and own brands in Malaysia, today announced the details of its proposed listing on the Main Board of The Stock Exchange of Hong Kong Limited ("HKEX").Swang Chai Chuan plans to offer a total of 241,000,000 shares under the Global Offering (subject to the Over-allotment Option), which comprises 216,900,000 Shares (subject to re-allocation and the Over-allotment Option) for the International Placing, and 24,100,000 Shares (subject to re-allocation) for the Hong Kong Public Offering. Based on the Offer Price HK$0.54 per Share (being the mid-point of the indicative offer price range of HK$0.52 to HK$0.56 per Share) assuming the Over-allotment Option is not exercised, after deducting estimated underwriting fees and other expenses, net proceeds from the Global Offering are estimated at approximately HK$86.0 million.The Hong Kong Public Offering will commence from 9:00 a.m. on 8 August 2022 (Monday) and end at 12:00 noon on 11 August 2022 (Thursday). Results of allocations are expected to be announced on 18 August 2022 (Thursday), and dealing of the Group's shares is expected to commence on the Main Board of HKEX on 19 August 2022 (Friday) under the stock code of 2321. Shares will be traded in board lots of 5,000 Shares each. Sunny Fortune Capital Limited is the Sole Sponsor and Sunny Fortune Capital Limited and Elstone Securities Limited are the Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers. BOCOM International Securities Limited, China Galaxy International Securities (Hong Kong) Co., Limited, CMBC Securities Company Limited, Haitong International Securities Company Limited and Phillip Securities (Hong Kong) Limited are the other Joint Bookrunners and other Joint Lead Managers.Investment HighlightsEstablished F&B distributor of Own Brands, international and domestic brands in MalaysiaSwang Chai Chuan is one of the top 5 companies(1) in Malaysia F&B distribution industry. With its long years of experience in and dedication to the F&B distribution industry in Malaysia, the Group has become an established local F&B distributor with substantial scale, supporting over 200 international and domestic brands. Third-Party Brands distributed by the Group included Oreo, Cadbury, Ajinomoto, a British multinational ice-cream frozen dessert brand and a New Zealand international dairy product brand. The Group has also served a number of well-established retail chains such as Nirwana, TF Value-Mart, BS Group and Sabasun. To establish the reputation and enhance the market penetration, Swang Chai Chuan is committed to offering a wide range of products under different brands to customers with timely delivery service. At the same time, the Group has received awards and recognitions by Malaysian associations in recognition of the excellent product and services, such as the Superbrands Status and the Sin Chew Business Excellence Awards.Strong sourcing network and long-term relationship with recognised international and domestic brand ownersThe Group distributed and actively managed the diverse portfolio of F&B and other brands of a wide selection of quality products covering 4,000 SKUs, which can be divided into nine different core categories, namely dairy products, frozen food, packaged food and commodities, sauce, oil and condiments, beverages and specialty products, personal and baby care products, pet care products and cleaning and kitchen supplies. The Group has established long-term business relationship ranging from approximately 5 to 26 years with its five largest suppliers to date, thus enabling the Group to ensure a stable supply of products.Since 2007, the Group started tapping into the development of certain Own-Brand Products, the variety of which was gradually expanded. The Group was able to provide different choices of F&B and other products to the customers under over 200 Third-Party Brands, consisting of approximately 140 international brands and approximately 80 domestic brands, together with products under five major Own Brands, such as CED, Mega Fresh, Mega Food, Sayangku and Snowcat, covering various product types and price ranges. Specialty products, salt, frozen seafood, frozen meat, and pet care products, etc. under the major Own Brands further enlarged the brand and product portfolio and consumer base of the Group. The Group will continue to explore new brands and products that are expected to have growth potential and to diversify the product offerings.Large and diverse customer base with a strong focus on large retail chains and channelsThe Group has established and maintained a large customer base with more than 11,000 active customers over the years with a focus on well-established retail chains. Many of the Group's customers are established international retail chains and local retail chains which make purchases frequently and in huge quantities. As a result of the effort to diversify customer portfolio, the Group also serves F&B dealers and merchandisers, school canteens, hospitality and other customers. As at 30 April 2022, the Group had established long-term business relationship with the five largest customers during the track record period ranging from approximately 11 to 26 years. The Group achieved high customer retention rate with revenue generated from repeat customer accounts contributing over 90% of the total revenue during the track record period. With the large and diverse customer base as illustrated above, the increasing scale and complexity of the customers' business operation have driven demand for F&B products sourced from suppliers that scale up the procurement and other business activities, thereby growing the revenue. The Group also enjoys economies of scale and continues to optimise its cost structure and increase its profitability.Expansive distribution network is strategically located and well equipped with temperature-controlled facilitiesThe Group's distribution network, which form the cornerstone of warehousing and logistics management services, can effectively facilitate the supply chain of F&B distribution and deliver products to more customers on a timely basis with delivery lead time as short as within 24 hours. The Group currently operated 12 warehouses strategically located in the major sales regions in Peninsular Malaysia, with designated storage capacity of approximately 25,600 CBM, nine of which are equipped with cold storage facilities with an aggregate of approximately 4,550 CBM mainly for storage of frozen food and dairy products. The Group also operated a fleet of over 140 self-operated logistics vehicles, of which approximately 100 are refrigerated trucks, which facilitate an effective and efficient flow of warehousing and logistics management operations.Proven track record of financial performanceDuring the track record period, the gross profit margin of the Group showed an upward trend, with the gross profit margin in FY2021 reaching 14.1%. Gross profit amounted to approximately RM94.5 million (equivalent to approximately HK$181.7 million) in FY2021, representing a year-on-year increase of approximately 18.5% from FY2020. Adjusted net profit also rose by approximately 29.9% year-on-year from FY2020 to approximately RM28.6 million (equivalent to approximately HK$54.9 million) in FY2021. (2)RM'000(approximately) FY2019 FY2020 FY2021 4M2022(As at 30 April)Revenue 497,435 564,632 668,738(equivalent to approximately HK$1,286,035) 266,652(equivalent to approximately HK$512,792)Gross profit 66,187 79,733 94,508(equivalent to approximately HK$181,746) 38,753(equivalent to approximately HK$74,525)Gross profit margin 13.3% 14.1% 14.1% 14.5%Adjusted net profit* 17,686 21,985 28,562(equivalent to approximately HK$54,927) 13,556(equivalent to approximately HK$26,069)Adjusted net profit margin* 3.6% 3.9% 4.3% 5.1%* Adjusted net profit was calculated based on the profit for the year excluding listing expenses during the track record periodDuring the track record period, the Group recorded ongoing growth in revenue, gross profit and adjusted net profit. At the same time, gross profit margin and adjusted net profit margin also continued to rise.Experienced and dedicated senior management teamThe Group has an experienced, dedicated and capable management team led by the executive Directors, the Soon Brothers, who have been instrumental in spearheading the growth of the Group and have over 30 years of experience in the business of distribution of F&B products in Malaysia. They are responsible for the overall business strategy, planning, operational and sales management and development of the Group. In addition, the Group has a loyal, experienced and capable senior management team with extensive operational expertise and in-depth understanding of the F&B distribution industry in Malaysia and is able to establish a high degree of product differentiation and a broad brand portfolio.Future Growth StrategiesFurther enhancing distribution and sales capabilities by investing in cold chain and other infrastructureDuring the track record period, the Group's revenue generated from frozen food and dairy products represented approximately 50% of the total revenue. Both frozen food and dairy products are sold by the Group under, in addition to Third-Party Brands, Own Brands or on a White-Label basis which generally have a higher profit margin as compared to the distribution and sales of Third-Party Brand Products. Going forward, the primary business strategies of the Group should pivot around enhancing the cold chain warehousing and logistics capabilities and management. The Group plans to (i) set up a new warehouse with cold storage facilities and upgrade the self-owned warehouses with advanced features; (ii) acquire and upgrade cold and other logistics vehicles; (iii) enhance cold chain and other management and information systems.Apart from cold storage facilities, the expected increase in designated general storage capacity would also facilitate the optimisation of the storage space and enhance the efficiency in sales of the products that are stored under general condition and improve the operational results.Enhanced development of Own ProductsOwn Products and White-Label Products generally enjoy a high gross profit margin, which drives the expansion of relevant segments. The Group plans to develop the business of the Own Products and White-Label Products by purchasing new processing machines for processing so as to take up more orders, save labour costs and enhance processing efficiency. The Group will also conduct marketing and promotional activities of the Own-Brand Products to further conduct media marketing and engage with more potential customers.Development of e-commerce business by launching a mobile applicationOwing to the large and diverse customer base with more than 11,000 active customers, the Group receives and processes a large number of orders from various types of customers every day. To streamline the ordering process and in line with the market trend, the Group plans to develop the e-commerce operations by engaging an external party service provider to design and customise a mobile application. The Ordering App is expected to be launched and put into use by the fourth quarter of FY2023 and it is expected to create a more convenient and pleasant purchasing experience for customers and enhance the efficiency of the Group.Strategic acquisitions and investments along the supply value chainIn view of the expected growth in the F&B distribution industry in Malaysia, the Group plans to continue to expand the business and explore potential business opportunities by acquiring majority or entire shareholding of, or investing in, local company(ies) or acquiring business(es) in the F&B supply value chain, including horizontal and vertical acquisitions and investments.Use of proceedsBased on the Offer Price of HK$0.54 per Share (being the mid-point of the indicative Offer Price range of HK$0.52 to HK$0.56 per Share) and assuming the Over-allotment Option is not exercised, after deducting estimated underwriting fees and other expenses, net proceeds from the Global Offering are estimated at approximately HK$86.0 million. The Group currently intends to use the net proceeds from the Global Offering for the following manner:Applications / Percentage-- To further enhance the distribution and sales capabilities by investing in cold chain and other infrastructure 47.8%-- To develop the Own Products business by acquiring new processing machines and conducting marketing and promotional activities 18.0%-- To develop e-commerce business by launching a mobile application 7.0%-- For strategic acquisitions and investments along the supply value chain 17.2%-- As general working capital 10.0%Cornerstone InvestmentThe Group has entered into cornerstone investment agreements with four cornerstone investors separately, namely Mr. Tee Kian Heng, Huihuang Resources Limited, Dato' Sri Ng Chong Keong and Dato' Sri Pek Kok Sam (each a "Cornerstone Investor" and together the "Cornerstone Investors"), pursuant to which the Cornerstone Investors have agreed to, subject to certain conditions, subscribe for such number of Shares (rounded down to the nearest board lot of 5,000 Shares) at the Offer Price, which may be purchased with an aggregate amount of approximately HK$47.0 million. The Group believes that introducing the Cornerstone Investors to the Global Offering and securing the subscription of a significant number of Offer Shares will set a solid platform for the launch of the Global Offering by demonstrating the Cornerstone Investors' confidence in the Global Offering.Swang Chai Chuan LimitedSwang Chai Chuan Limited is one of the top 5 companies* in Malaysia F&B distribution industry and is an established distributor of F&B and other products for recognised international and domestic third-party brands and own brands. Swang Chai Chuan Limited also provides suppliers with warehousing, logistics, sales and marketing support and other value-added services* In terms of revenue in 2021, according to Frost & SullivanCapitalised terms used herein shall have the same meanings as those defined in the prospectus dated 8 August 2022, unless the context otherwise requires.Media enquiries:Strategic Financial Relations LimitedVeron Ng Tel: (852) 2864 4831 Email: veron.ng@sprg.com.hkMel Lai Tel: (852) 2864 4855 Email: mel.lai@sprg.com.hkAggie Fang Tel:(852) 2114 4987 Email: aggie.fang@sprg.com.hkNotes:(1) In terms of revenue in 2021, according to Frost & Sullivan(2) These amounts are converted from Malaysian Ringgit to Hong Kong dollars or Hong Kong dollars to Malaysian Ringgit at an exchange rate of RM0.52 to HK$1.00. No representation is made that Malaysian Ringgit/Hong Kong dollars amount have been, could have been or may be converted to Hong Kong dollars/Malaysian Ringgit at that rate or at all.Important:1. This press release is for information purposes only and does not constitute or include any recommendation or invitation or offer (nor is calculated to invite such a recommendation, offer or invitation) by any person for acquisition, purchase or subscription of the securities of the Company nor does it intend to act as a recommendation of the sale of securities or any invitation or offer for acquisition, purchase or subscription of securities. This press release should accordingly not amount to an advertisement or invitation within the meaning of section 103(1) of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) or a prospectus or an extract from or abridged version of a prospectus within the meaning of sections 2 and 38B, respectively of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). Investors should read the prospectus of the Company for detailed information about the Company and the proposed offering before deciding whether or not to purchase any securities of the Company. An application to subscribe for the shares referred to in this press release by any persons shall be made solely based on the prospectus and the application forms to be issued by the Company on 8 August 2022. 2. No application for the shares of the Company should be made by any person nor would such application be accepted without the completion of a formal application form or other application procedure that is issued with or in respect of the prospectus.3. The directors of the Company collectively and individually accept full responsibility for the accuracy of the information contained in this press release and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts the omission of which would make any statement herein misleading. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Waste-to-Energy Company in Singapore Made a Wholly-Owned Subsidiary JCN Newswire

Waste-to-Energy Company in Singapore Made a Wholly-Owned Subsidiary

TOKYO, Aug 8, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) and Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), part of MHI Group, have made a wholly-owned subsidiary of TuasOne Pte. Ltd., a special purpose company (SPC) for the business of the construction and operations of a waste-to-energy (WTE) facility in Singapore. Following the start of liquidation of Hyflux Ltd., a major water treatment and supply company in Singapore that held 75% of the issued shares in TuasOne, MHI and MHIEC jointly agreed with Hyflux to additionally acquire the shares of TuasOne held by Hyflux(1) to continue its business.Waste-to-Energy plant in Singapore which MHI Group independently provides O&M businessTuasOne is an SPC jointly established in 2015 by MHI and Hyflux. Formed under a public-private partnership (PPP) scheme, TuasOne has concluded a concession contract with the National Environment Agency (NEA) of Singapore to build and operate a WTE facility equipped with a stoker furnace type incinerator(2) for a period of 25 years. The facility has processing capacity for municipal solid waste (MSW) of up to 3,600 tonnes per day (tpd), and generation capacity of 120 megawatts (MW) of electricity, in the Tuas district of Southwest Singapore.The facility for which MHI Group has delivered incinerators and power systems consists of 4 boilers, capable of processing around 35% of the incinerable waste generated daily in Singapore. In December 2019, an MHI subsidiary in Singapore, Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. (MHI-AP), took over construction works of the WTE plant from Hyflux Group, which had been originally awarded the TuasOne project. MHI-AP completed construction in December 2021 and provided operations and maintenance (O&M) services for the facility. Since July 2022, this O&M business has been taken over by MHIEC Eco Creation Singapore Pte. Ltd., an O&M business SPC, newly established by MHIEC in Singapore. This project is the first time for the MHI Group to provide a fully integrated solution, from investment to construction, operations and maintenance, for a WTE facility outside Japan.MHI Group has one of the industry's most extensive track records for delivering WTE plants and other facilities in Southeast Asia. The group contributes to lowering the environmental load by efficient utilization of energy. It has been responsible for the engineering and construction of four WTE plants in Singapore, such as the Tuas South Incineration Plant (TSIP) completed in 2000, which has a nominal processing capacity of 3,000 tpd.In future, MHI Group will leverage this experience with independent participation in an overseas WTE concession project and stable plant operations to establish its operational expertise and successful business model, and through its efforts on expanding orders for PPP projects, which in recent years have become mainstream in the environment-related market in broader areas such as Southeast Asia and the Middle East. MHI Group will continue to work toward resolving global environmental issues and achieving a carbon- neutral society.(1) MHI will hold a 25% stake in the company, and MHIEC the remaining 75%.(2) A stoker furnace is an incinerator in which waste is combusted as it is forced upward and moves along on a fire grate made of heat-resistant castings.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More

天寳集团主席洪光椅以新股份方式收取末期股息,增持约2,975万新股

EQS 新闻 via SEAPRWire.com / 2022-08-03 / 14:41 UTC+8 【请即时发布】 2022年8月3日 Ten Pao Group Holdings Limited 天寳集团控股有限公司 (股份代号:1979.HK) 主席洪光椅以新股份方式收取末期股息,增持约2,975万新股 天宝集团控股有限公司(「天寳集团」或「本公司」) (股份代号:1979.HK)于2022年7月27日获本公司主席兼行政总裁及控股股东洪光椅先生(「洪先生」)通知,洪先生及其联系人(定义见上市规则)已按本公司于2022年7月15日所公布的有关截至2021年12月31日止年度末期股息的以股代息计划(「以股代息计划」),选择以新股代替现金方式收取末期股息。按以股代息计划每股新股的股价1.234港元计算,洪先生及其联系人将获发行29,749,521股新股,紧随增持股份后,洪先生及其联系人将持有685,301,521股股份。 本公司管理层表示:「是次洪先生透过以股代息增持本公司股份,反映其对本公司的前景有充分信心。公司近年进军极具潜力之新能源汽车充电和便携式储能业务,目前已经与新能源汽车充电桩生产商以及多个国际品牌合作,推出商用、零售两大类别新能源产品,销售进度令人鼓舞。目前已经推出的产品包括新能源汽车充电桩核心组件、高功率充电组件、新能源汽车手提充电枪及便携式储能箱。迎合国际市场的整体环保意识提高,新能源汽车得到政商界广泛推广,相信本集团丰富的产品组合能掌握先机,抢占市场份额,成为一大业绩增长动力,为股东带来长远而丰厚的回报。」 -完- 关于天宝集团控股有限公司 天宝始创于1979年,2015年在香港主板上市,专注电源技术研发超过40年,为不同的客户及不同的终端领域,提供设计和制造安全可靠、具有市场竞争力的「一站式智能电源解决方案」。集团多年来成功与全球多个国际品牌建立了良好业务关系,不断拓展巩固客户基础,同时作为国内增长迅速的领先品牌的主要供货商。于2020年,天宝成立新能源事业部,着手投放重点资源于新能源产品的研发及制造。 此新闻稿由金通策略有限公司代天宝集团控股有限公司发布。 如有查询,请联络: DLK Advisory 金通策略 电话: +852 2857 7101 传真: +852 2857 7103 2022-08-03 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More
Fujitsu and Hokuhoku Financial Group develop algorithm for efficient flood risk calculation for Task Force on Climate-related Financial Disclosures (TCFD) reporting JCN Newswire

Fujitsu and Hokuhoku Financial Group develop algorithm for efficient flood risk calculation for Task Force on Climate-related Financial Disclosures (TCFD) reporting

TOKYO, Jul 28, 2022 - (JCN Newswire via SEAPRWire.com) - Fujitsu and Hokuhoku Financial Group, Inc. (hereinafter Hokuhoku FG)(1) today announced the development of an algorithm to support information disclosure in line with the recommendations of the Task Force on Climate-related Financial Disclosures (hereinafter TCFD)(2). The two companies conducted trial demonstrations and confirmed the efficiency of the new algorithm in supporting customers in improving their operational efficiency when preparing for TCFD reporting.The new algorithm developed by Fujitsu automatically arranges customer data and hazard data issued by the government on a map to calculate the physical risk of a customer or asset in the event of a flood. The analysis results will be used in the integrated report of Hokuhoku FG that will be issued on July 29, 2022.Moving forward, the two companies will continue to verify the effectiveness of the newly developed algorithm for customers in the financial industry with a large number of clients, and plan to expand it to customers in other industries in the future.BackgroundClimate change poses a major, ongoing economic threat, and not only listed companies but also many affiliated companies are increasing their efforts to resolve the myriad issues related to global warming. Underlining the growing significance of this responsibility, players in various industries increasingly focus on TCFD as a measure to disclose climate-related financial information.In Japan, since April 2022, companies listed on the Tokyo Stock Exchange's Prime Market are required to disclose TCFD information, and the impact of climate-related risks on companies and their measures to mitigate its impacts have been attracting growing attention. Companies situated in flood-prone areas are especially vulnerable, as they are continuously exposed to significant risks that can affect the continuity of their business.The implementation of cross-industry measures that also include players such as logistics companies that transport goods and institutions that finance climate change initiatives represent an ongoing task.To address this issue, Fujitsu and Hokuhoku FG developed new measures to accurately and efficiently measure flood risks, which represent a high-priority issue within climate-related risks.Outline of the trial demonstrationsFujitsu and Hokuhoku FG conducted trial demonstrations of the newly developed algorithm from November 2021 to March 2022 for real estate collateral of the Hokuriku Bank and the Hokkaido Bank. Leveraging Fujitsu's IT technology and Hokuhoku FG's knowledge of risk management practices, the two companies systematized a process to plot customers' properties on a hazard map and predict potential flood risks. As a result, Hokuhoku FG employees were able to streamline approximately 850 hours of manual work time and to improve efficiency in their preparation for TCFD reporting. The two companies further confirmed the effectiveness of the newly developed algorithm in correctly measuring flood risks.Future PlansWith the aim to become an environmentally advanced financial group, Hokuhoku FG will utilize its broad customer base to explore new services that support suppliers' efforts to realize their ESG/SDGs related objectives and decarbonization.Fujitsu will continue verifications of the newly developed algorithm starting with the financial sector where it expects to generate strong interest. Fujitsu further plans to combine this algorithm with initiatives aimed at reducing CO2 emissions of industries including the logistics industry, which remains one of the most important areas in which society's infrastructure faces disruption by potential flood risks. Both Fujitsu and Hokuhoku FG will continue their efforts to contribute to the sustainable development of local economies and communities.(1) Hokuhoku Financial Group, Inc. :Headquarters: Toyama Prefecture, Toyama City; President: Hiroshi Nakazawa(2) TCFD: "Task Force on Climate-related Financial Disclosures" - Disclosure in line with the recommendations of the Task Force on Climate-related Financial Disclosures. Established by the Financial Stability Board (FSB) to examine how to conduct climate-related disclosure and respond to financial institutions. Companies listed on the Tokyo Stock Exchange's Prime Market are required to disclose information on climate change-related risks and opportunities in line with TCFD recommendations.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$32 billion) for the fiscal year ended March 31, 2022 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
The 7th Quam IR Awards was Successfully Held ACN Newswire

The 7th Quam IR Awards was Successfully Held

HONG KONG, Jul 27, 2022 - (ACN Newswire via SEAPRWire.com) - The award presentation ceremony of Quam IR Awards 2021 ('QIRA' or 'The Awards') successfully took place on 27 July, 2022 at Four Seasons Hotel Hong Kong, recognizing investor relations professionals capable of assisting their companies in adapting to changes and, with outstanding governance thinking and practical strategies skills, taking their companies towards sustainable development in the ever-changing business environment. Management of Tonghai Financial Group, including, Mr. Stacey Wong, Chief Operating and Risk Officer, (fifth from the left), Mr. Chris Wu, Chief Financial Officer (second from the right) , Mr. Army Yan, Chief Investment Officer of Tonghai Financial Group (first from the left) and Ms. Sandy Lam, Managing Director of Hong Kong Sustainability Strategic Advisory Limited (second from left), took picture together with award presenters and representatives of awarded companies.Celebrating IR Excellence Quam IR Awards is proud to recognize and reward the very best listed company in the investor relations industry. The winners of the QIRA have opened the door of communication through diversified channels, representing the tact and professionalism of investor relations. The keen enthusiasm for the 7th Quam IR Awards can be seen from the entries. A total of 15 companies have differentiated themselves from their competitors to win the Awards. Partnered with Professional Institution, Giving Commendations to Sustainable Companies With the environment, social and governance becoming increasingly important factors that affect the strategies and operation of listed companies, China Tonghai IR has partnered with Hong Kong Sustainability Strategic Advisory Limited (HKSSA), an advisory firm focusing on enterprises' abilities of their sustainable development, granting "Sustainable Development Category" - Platinum, Gold, Silver and Bronze awards from a professional perspective to honour companies demonstrating excellence in all 3 areas of ESG. In particular, a special award "Sustainable Development Category - The Best Report of the Year" has been added this year. It is delighted to announce Lenovo Group Limited becoming the first awarded company to achieve this honor. Quality Enterprises Further Reinforce Hong Kong's Position as International Financial CentreMr. Chris Wu, Chief Financial Officer of Tonghai Financial Group, said in the opening remark "The winning companies demonstrate the multiplicity, dynamics, outstanding corporate governance and culture of the business community of Hong Kong. Together with these important elements, it enhances Hong Kong's status as International Financial Center, meanwhile, it brings additional economic activities to the capital markets." Mr. Stacey Wong, Chief Operating and Risk Officer of Tonghai Financial Group, said "Hong Kong has made a tremendous effort in introducing emerging and high growth companies onto the stock exchange, like the acceptance of weighted voting rights, pre-revenue biotech companies and SPAC. There has also been an increasing number of dual listings of US-listed Chinese companies. We are certain that more companies, in the old and new economy alike, will be attracted to Hong Kong. You from the investor relations profession play a vital role in educating investors on the potential and development of business models new to them, as well as resuscitate the value of old economy companies."Unwavering Support from Business Community and Media friends Tonghai IR was honoured to invite Mr. Joseph Chan, JP, Under Secretary for Financial Services, Dr. Anthony Fan, Founding President of The Hong Kong Independent Non-Executive Director Association, Dr. Michael Chan, Honorary Chairman of Hong Kong Institute of Marketing and Dr. Sam Kwok, President of Hong Kong Society of Economists as our guests of honour to witness such grand occasion. The 7th Quam IR Awards came to a successful conclusion, thanks to our supporters in the business community, media friends and sponsors in Hong Kong and mainland China. Our supporting media partners include The Chamber of Hong Kong Listed Companies, The Hong Kong Independent Non-Executive Director Association, Ming Pao, The Standard, FX678 and StockStar. Tonghai IR is grateful for the strong support and generous sponsorship from Green Common and HKTaxi, which make Quam IR Awards 2021 a success.The list of awardees for Quam IR Awards 2021 (In alphabetical order of company name):Stock Code / Company NameHong Kong Index Constituents (Hand Seng Index) Category2020 ANTA Sports Products Limited 2382 Sunny Optical Technology (Group) Company LimitedMainboard Category1761 Babytree Group0081 China Overseas Grand Oceans Group Limited 1929 Chow Tai Fook Jewellery Group2232 Crystal International Group Limited 0173 K. Wah International Holdings Limited 0826 Tiangong International Company LimitedSustainable Development Category - Platinum3311 China State Construction International Holdings Limited2232 Crystal International Group Limited0992 Lenovo Group LimitedSustainable Development Category - Gold2020 ANTA Sports Products Limited 3718 Beijing Enterprises Urban Resources Group Limited0081 China Overseas Grand Oceans Group Limited Sustainable Development Category - Silver1761 Babytree Group1229 Nan Nan Resources Enterprise Limited0152 Shenzhen International Holdings LimitedSustainable Development Category - Bronze0227 First Shanghai Investments Limited 2266 Lai Si Enterprise Holding LimitedSustainable Development Category - The Best Report of the Year0992 Lenovo Group LimitedWebsite of Quam IR Awards 2021: https://eventedm.tonghaiir.com/QIRA2021-22/EN_US/For enquiries, Tonghai IRMarketing & PR contact:Mandy Lo T: 2217-2753 Email: mandy.lo@tonghaifinancial.comCharlie Chan T: 2217-2504 Email: charlie.chan@tonghaifinancial.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1

HONG KONG, July 26, 2022 - (ACN Newswire) - The aging of the population is accelerating, pharmaceutical technology is constantly updating, and the development of the global pharmaceutical industry continues to accelerate. The pharmaceutical market is expected to maintain a growing trend. According to Frost & Sullivan, the global pharmaceutical market is expected to reach $1,711.4 billion by 2025. Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. discovery and development of new small molecules and biologics, and systematic screening of existing approved drug molecules, etc.; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research. Currently, Aptorum Group's R&D pipelines cover the ALS family of drugs and the SACT family of drugs, covering such indications as drug-resistant Staphylococcus aureus (including MRSA), Gram-positive cocci, influenza A, COVID-19, orphan disease neuroblastoma and other cancers. Since the beginning of this year, Aptorum Group has accelerated its research and development (R&D), with major breakthroughs achieved in several pipelines under development. SACT-1, the Group's orally administered small molecule drug for the treatment of neuroblastoma, was granted its first patent by the United States Patent and Trademark Office (US PTO) in November 2021 and Orphan Drug Designation by the US Food and Drug Administration (FDA) at the beginning of this year. Meanwhile, the Group completed the Phase I clinical trial of SACT-1 in January this year and announced the finalized data in May. The data showed that SACT-1 had impressive safety and good tolerability making the later stages of SACT-1 promising. In addition, earlier in the year, the Group launched oncology and autoimmune discovery and development platform targeting unmet mutations and novel biomarkers, focusing on indications including non-small cell lung cancer ("NSCLC") and autoimmune diseases such as lupus, rheumatoid arthritis and inflammatory bowel diseases. In the meantime, the Group also completed a Phase I clinical trial for ALS-4, a first-in-class anti-virulence-based small molecule drug targeting infections caused by Staphylococcus aureus including MRSA. In the second quarter of this year, the Group's Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics ("RPIDD") was granted a patent by the US PTO, and the Group is spearheading the efforts in the ongoing clinical validation and pre-commercialisation preparation of the technology. Currently, the overall development prospect of the biopharmaceutical industry is promising. Aptorum Group is actively advancing its R&D projects. With its strong R&D capabilities and internal management capacity, it is expected to further enhance its business development, expand the room for enterprise development, and gain greater development opportunities in the biopharmaceutical industry.
More
USMining Group Officially Announced that It Has Obtained the US MSB License ACN Newswire

USMining Group Officially Announced that It Has Obtained the US MSB License

HONG KONG, Jul 22, 2022 - (ACN Newswire via SEAPRWire.com) - The US MSB (Money Services Business) license is a financial license provided by FinCEN, the Financial Crimes Enforcement Bureau of the US Treasury Department. FinCEN publishes MSB, which stands for Money Services Business. MSB is the starting point for blockchain payment firms. The accomplishment of USMining Group in acquiring a US MSB license is important positive news for investors.Since its inception, USMining Group has attracted the attention of the blockchain industry. USMining Group thinks that blockchain technology requires practical applications as well as public involvement. It is vital to decrease the barrier to blockchain investment. USMining Group was able to acquire the public's trust in a short amount of time, and the US MSB license became the key to market development.The USMining Group team claims that "Previously, we primarily provided system development and maintenance assistance to enterprises and huge financial institutions. Because of the emergence of blockchain in recent years, the firm has opted to pursue a broader end-user market. Ideally, it would be feasible to make money, develop communities, amass traffic, form consensus, and eventually build a blockchain ecosystem using USMining Group's technology."About USMining Group USMiningGroup, created in 2016, is a cloud mining equipment sharing platform located in the United States. USMiningGroup is a pioneer in the realm of ASICs, or specialized devices, and it develops Cryptomining equipment under the Bitminer name. As a result, it is considered one of the greatest Crypto cloud mining sites.This company also works with two of the world's largest cryptocurrency mining pools, Bitpool and BTC.com. USMiningGroup saves customers the trouble of obtaining and maintaining their own mining equipment. By acquiring a contract, users may mine digital currencies and earn money.Media ContactBrand: USMining GroupE-Mail: info@USmininggroup.comWebsite: https://usmininggroup.com SOURCE: USMining Group Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
IBI Group公布二零二二财年全年业绩 面对市场挑战展现强韧抗逆力 ACN Newswire

IBI Group公布二零二二财年全年业绩 面对市场挑战展现强韧抗逆力

HONG KONG, Jun 30, 2022 - (亚太商讯 via SEAPRWire.com) - IBI Group Holdings Limited (「IBI」或「公司」,及其附属公司统称为「集团」;股份代号:1547)为一家专注于投资在建筑环境相关业务的上市控股公司,今日公布截至二零二二年三月三十一日止财政年度(「二零二二财年」)之业绩。于回顾年内,集团的收益录得约405.9百万港元(二零二一财年:约556.7百万港元),毛利约为68.0百万港元(二零二一财年:79.4百万港元),公司拥有人应占溢利约为27.0百万港元,而上一财政年度约为54.4百万港元(当中包括集团策略投资分部的一次性溢利约43.6百万港元)。每股基本及摊薄盈利为3.4港仙(二零二一财年:6.8港仙)。集团保持强劲的财务状况,截至二零二二年三月三十一日止之现金及现金等价物达约为141.6百万港元(二零二一财年:87.1百万港元),并无银行借款。董事会建议派发截至二零二二年三月三十一日止年度之末期股息每股1.0港仙(二零二一财年:4.0港仙)。业务回顾1. 承建IBI在香港及澳门提供世界级的室内装修及楼宇翻新服务,涵盖两大类项目,分别为装修项目以及改建和加建项目。基于良好声誉及彪炳往绩,即使在Covid-19疫情的持续影响下,公司的香港部门于二零二二财年依旧忙碌,年内完成11个装修项目并获授14个项目。于回顾年内,集团录得来自承建分部的收益约403.9百万港元(二零二一财年:511.0百万港元),分部毛利激增91.0%至约67.4百万港元。2. Building solutions于二零二零年四月,IBI成立附属公司Building Solutions Limited(「BSL」),提供可提升建筑环境表现及福祉的产品及服务,以为用者提供现代、健康及高性能的空间。回顾年内,BSL一直努力发展业务及争取订单。于营运的第二年,其市场渗透率明显大幅上升,销售数据录得改善。新获得分销权的尖端照明产品广受好评,这将反映在下一个财政年度的销售数据之中。于二零二二财年,BSL录得分部亏损约2.7百万港元。3. 策略投资于本财政年度,集团部分剥离其早期股票投资,该等投资于上一个报告期间产生显著回报。此外,集团的房地产相关投资交易亦取得巨大的早期成功。于二零二二财年后期,集团于日本北海道取得紧邻规划中的新干线(高速铁路线)未来站台的建设用地,现正与当地发展专家合作,以确定如何有效利用该土地以及其发展时机。展望未来,集团将继续寻求潜在投资机会。于财务报告期后,集团收购位于爱尔兰都柏林市中心的大楼Adelaide Chambers。该投资是一座约20,000平方英尺商业办公空间的旧式建筑,极具升值潜力,待进行大楼升级及租赁改善等升级项目后,可望增加资产的整体价值,并为集团带来额外利润。展望未来香港现时已解除疫情期间实施的诸多限制,生活正迅速回归正常。集团相信,待严格的检疫限制进一步减少,市场环境逐步稳定下来,商业活动将恢复正常,届时香港将重拾其国际地位。展望未来,集团相信分配予投资的资本将于下一个财政年度悉数归属。IBI主席兼行政总裁Neil Howard先生表示:「尽管COVID-19大流行带来前所未有的挑战,但我们依然坚定地推动增长和投资策略。IBI对来年充满期盼,相信随着我们慢慢进入疫情后期,营商环境将不断改善。得益于策略业务决定,IBI继续表现稳定,在如此艰难的时刻能够留住全体员工,实在让我们感到十分自豪。此外,我们很高兴看到附属公司,尤其是BSL的增长,并期待公司从初创踏入发展阶段后,财务状况将显著录得改善。二零二二财年的业绩证明我们有能力提供综合创新解决方案,我们期待未来能为股东带来更强劲的业绩,创造更多长远价值。」关于IBI Group Holdings Limited(股份代号︰1547)IBI Group Holdings Limited 为香港主板上市控股公司,专注于建筑环境方面的投资。集团的主要投资领域包括建筑和装修承建、提供创新和节能照明及空气质量检测产品的企业,以及寻找房地产开发和其他建筑环境的投资机会。集团以提供多项专业及优质的产品、服务和客户体验为宗旨,为客户提供具有创新、可持续性、具环境敏感性和影响力的体验。有关IBI Group Holdings Limited的详情,请浏览网站:https://ibighl.com/. Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)
More
EC Healthcare and Yoho Group Form Strategic Partnership ACN Newswire

EC Healthcare and Yoho Group Form Strategic Partnership

HONG KONG, Jun 30, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces that the Group signed a memorandum of understanding with Yoho Group Holdings Limited ("Yoho Group", SEHK stock code: 2347) for strategic collaboration. The partnership will be focused on accelerating the growth of medical, aesthetic medical and beauty and wellness services in the e-commerce market, and jointly boosting the e-commerce penetration of medical, aesthetic medical and beauty and wellness services in Hong Kong. The partnership will strengthen ECH's online presence in Hong Kong and expand its customer base and further consolidate the leading market position.Under the collaboration, (i) The Group will become Yoho Group's anchor merchant in beauty and healthcare services and Yoho Group will launch an online medical, aesthetic medical and beauty and wellness service zone. The dedicated section will enable the Group to reach a greater public domain traffic flow from the e-commerce platform with strong client synergy in the healthcare and beauty sector;(ii)Both Parties will strengthen their co-marketing efforts to increase the overall sales volume and promote product cross-sell; (iii) Both Parties agree to exchange know-how in precision marketing and consumer behavior analysis in healthcare and beauty sector, in order to develop more comprehensive digitalized marketing strategy to improve overall customer lifetime value; (iv) Both Parties will devote resources to jointly enhance technical solutions across social & mobile commerce, data-driven marketing, and fulfillment efficiency to streamline the entire consumer journey.Mr. Gemini Wong, Executive Director, Chief Digital Officer and Deputy Marketing Officer of EC Healthcare said, "The Group is delighted to establish a strategic partnership with Yoho Group. Through the collaboration, we hope to leverage Yoho Group's experience regarding online retail and the extensive reach to the accumulated customer traffic to boost the Group's e-commerce, diversify the digital marketing strategies and optimize the e-commerce experience so as to increase the overall sales volume, and raise the brand awareness and consolidate the leading position."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, focusing on preventive and precision medicine and leveraging investment in IT, brand, service and corporate culture to build a diversified enclosed healthcare ecosystem with the mission to bring health, beauty and happiness to everyone. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, a advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021About Yoho Group Holdings Limited Yoho Group Holdings Limited is one of the leading e-commerce platforms in Hong Kong, with more than 820,000 registered users as of the date of this announcement and over 2,290,000 monthly active users (based on the data in March 2022). According to Frost & Sullivan's data and the Group's revenue for the financial year ended 31 March 2021, the Group recorded the highest online retail sales among e-commerce players in consumer electronics and home appliances and acquired a market share of approximately 5.6%. Leveraging its vast customer base, the Group is expected to launch its online marketplace operations in the financial year ending 31 March 2023 to expand the product and service offerings for its customers. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Jacobson Pharma Announces FY2022 Annual Results ACN Newswire

Jacobson Pharma Announces FY2022 Annual Results

HONG KONG, Jun 29, 2022 - (ACN Newswire via SEAPRWire.com) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").KEY HIGHLIGHTS-- Year-on-year revenue up by 10.3%, amounting to HK$1,595.5 million -- Profit for the year up by 78.4%*, amounting to HK$187.7 million-- Strong growth witnessed on key therapeutic classes for chronic diseases such as lipid lowering agents and angiotensin II inhibitors -- Progress with expansion plan in Greater China as facilitated by Greater Bay Area ("GBA") healthcare policy and formation of joint venture with an established partner-- Delivery of approximately 9 million doses of Fosun BioNTech Comirnaty Vaccine in Hong Kong and Macau for the collaborative fight against COVID-19 During the Reporting Period, the Group delivered total revenue of HK$1,595.5 million with a year-on-year growth of 10.3%, primarily driven by the solid growth momentum of business in the public sector. The profit from operations and profit for the year was registered at HK$260.9 million and HK$187.7 million, representing a promising growth of about 48.9%* and 78.4%* respectively, as compared to the adjusted profit from operations* and adjusted profit* for the corresponding year of 2021. The Group's financial position remains stable as supported by a healthy cash flow, with adjusted earnings before interest, taxes, depreciation and amortisation (adjusted EBITDA) posted at HK$441.6 million for the Reporting Period and a net gearing ratio at 29.2% as of 31 March 2022. With a cash balance of HK$478.7 million as of the end of the Reporting Period, the Group also recently secured a syndicated loan of HK$1.4 billion to enhance its capital capability. The Board has recommended the payment of a final dividend of HK2.68 cents per share (FY2021: HK1.50 cents per share). Excluding the FY2021 special interim dividend in the form of distribution in specie of shares of JBM (Healthcare) Limited (Stock code: 2161.HK), an indirectly non-wholly owned subsidiary of the Company, total dividend for the Reporting Period amounts to HK3.88 cents per share (FY2021: HK2.30 cents per share), an increase of 68.7%.Solid Performance of Generics BusinessThe Group's generic drugs business demonstrated a resilient performance amidst the COVID-19 pandemic, presenting a solid growth of 13.6%, with revenue posted at HK$1,191.3 million for the Reporting Period. The Group's product offerings in the key therapeutic classes for chronic diseases such as diabetes and cardiovascular disease achieved high double-digit growth. For instance, the lipid-lowering product class recorded a strong growth of 37.2% in sales during the Reporting Period. In addition, the oncology drug class has also shown a significant growth of 572.6%, owing to the increased acceptance of the new Arsenic Trioxide Oral Solution.As a major supplier of essential medicines in Hong Kong, the Group responded swiftly to cater to the surged demand for medications during the fifth wave of the epidemic. This was reflected by the strong growth in the Group's analgesics (+18.6%), cough & cold preparations (+45.8%) and anti-inflammatory products (+77.5%). Steady Pipeline and Portfolio EnhancementThe Group continued to make steady progress with its research and development ("R&D") pipeline. As of 31 March 2022, the Group has a total of 172 products in the pipeline, among which 54 items have been approved for registration, 15 of them have been submitted for registration, 52 items have finished the development stage and are under stability preparation or stability study, plus 25 items are currently under formulation or pre-formulation research development stage.As a continuous drive for portfolio enhancement, the Group launched a number of new products during the Reporting Period, including Rabeprazole Tablets, Valsartan and Amlodipine Tablets, Telmisartan and Hydrochlorothiazide Tablets, Pregabalin Capsules, Atosiban Injection, and Idarubicin Injection. Additionally, the Group has secured the registration approvals for a group of new products such as Levetiracetam Tablets, Febuxostat Tablet, Dexmedetomidine Infusion, Pramipexole Extended Released Tablets, Brimonidine and Timolol Eye Drops, Telmisartan and Amlodipine Tablets for upcoming market launches. Tapping Specialty Drugs Market in China and AsiaFacilitated by new measures under the "Work Plan for Regulatory Innovation and Development of Pharmaceutical and Medical Devices in the Guangdong-Hong Kong-Macau Greater Bay Area", the Group has established collaboration with the University of Hong Kong-Shenzhen Hospital for the introduction of its Arsenic Trioxide Oral Solution (indicated for the treatment of acute promyelocytic leukaemia) into designated hospitals in the Greater Bay Area. The collaboration will also be part of a multi-centre clinical trial covering Guangdong, Singapore and Hong Kong. More recently, the Group, together with its non-wholly owned subsidiary, JBM (Healthcare) Limited (Stock code: 2161.HK), formed a joint venture with Ban Loong Holdings Limited (Stock code: 0030.HK), a company of which Yunnan Baiyao Group Co., Ltd (Stock code: 0538.SZ) is the controlling shareholder, to capture the growth opportunities of the specialty medicines in Greater China and the Asia-Pacific region. The joint venture will be primarily engaged in exploring business opportunities in various growth streams including specialty medicines (including orphan drugs), over-the-counter drugs, and branded healthcare products as well as medical devices in the Greater China region.Distribution of Fosun BioNTech Comirnaty Vaccine in Hong Kong and MacauThe Group is the exclusive distributor of Fosun BioNTech Comirnaty Vaccine (the "Vaccine") in Hong Kong and Macau. Up to the end of the Reporting Period, the Group delivered approximately 9 million doses of the Vaccine to the Department of Health and community vaccination centres in Hong Kong and the Macau governments. To protect the public against COVID-19 and help ensure herd immunity through vaccination, the Group is committed to supporting the governments and professional partners in the acceleration of vaccination in Hong Kong and Macau, especially among the elderly, and will continue to collaborate with the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and its subsidiaries to supply booster vaccination doses for the public, as encouraged by the health authorities.Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, concluded, "While the pandemic continues to impact the market environment, the Group delivered a solid performance in FY2022 by focusing on strong execution, bolstered by our core capabilities and enhanced product pipeline and portfolio. We also take pride in playing a collaborative role in the distribution of the Fosun BioNTech Comirnaty Vaccine in Hong Kong and Macau and have demonstrated our commitment to robust manufacturing and logistics operations by ensuring a continuous supply of our essential medicines were delivered to hospitals and patients during Hong Kong's fifth wave of the epidemic."Looking ahead, we are entering 2022 with positive momentum as we aim to build a differentiated portfolio that anticipates future healthcare needs. By executing our R&D and in-licensing strategies, fostering strong partnerships, and cementing our foothold in key strategic markets, we will further diversify and transform our business, bringing sustainable growth and value to shareholders."About Jacobson Pharma Corporation Limited (Stock Code: 2633)Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 10 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.The Group aims at the continued strategic enrichment of its generic drug portfolios through the addition of high-value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com * Excluding the one-off Employment Support Scheme subsidy from the Hong Kong Government of about HK$81.1 million in FY2021 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
China Wantian Announces its Annual Results ACN Newswire

China Wantian Announces its Annual Results

HONG KONG, Jun 28, 2022 - (ACN Newswire via SEAPRWire.com) - China Wantian Holdings Limited ("China Wantian" or the "Group"; stock code: 01854.HK) is pleased to announce its audited annual results for the year ended 31 March 2022 (the "financial year" or the "year under review"). Mr. HOOY Kok Wai (left), Chairman of the Board and Executive Director; and Mr. ZHONG Xueyong (right), Chief Executive Officer and Executive Director of China Wantian host the opening and unveiling ceremony of the Group's Zhongshan Branch.During the year under review, China Wantian continued to operate its business in Hong Kong. The Group is principally engaged in sourcing, processing and supplying food ingredients, with a focus on the provision of vegetables and fruit to food service operators in Hong Kong. It currently supplies in excess of 1,300 food ingredients to more than 480 customers. Leveraging the relaxation of social distancing measures and 2021 Consumption Voucher Scheme by Hong Kong government, the local consumer sentiment and operating environment in the catering industry gradually improved. Benefitting from an increase in orders with signs of revival in the food and beverage sector, the revenue of the Group recorded remarkable growth prior to the outbreak of the fifth wave of COVID-19 in Hong Kong. Total revenue of the year increased by approximately 19.7% year-on-year to approximately HK$127.7 million, with gross profit and gross profit margin of approximately HK$18.7 million (Year ended 31 March 2021: HK$13.2 million) and 14.6% (Year ended 31 March 2021: 12.4%) respectively. However, in support of its business development and expansion, higher operating expenses were incurred during the year under review, among which were legal and professional fees accrued in relation to the general offer. A provision for expected credit losses of approximately HK$5.4 million was recognised following the assessment of the credit history of its customers and market conditions during the year under review, loss for the year of approximately HK$11.0 million was subsequently recorded. The Board does not recommend the payment of a final dividend for the financial year (Year ended 31 March 2021: Nil).In May 2022, the Group established its Greater Bay Area headquarters in Shenzhen's Nanshan district, marking its official debut in the high-potential Greater Bay Area market. At the same time, the Group announced that it will double its effort to develop three main businesses including fresh food supply, retail and catering, as well as environmental protection and technology, grasping opportunities and actively enhancing its brand recognition in the Greater Bay Area, in order to expand its customer base and market share while enhancing diversity in business and maintaining its competitiveness.With regards to fresh food supply business, the Group will capitalise on its advantages in Hong Kong supply chain business, exercising superior task management in respect of procurement, orders, inventory, receipt and delivery, boosting efficiency to deliver fresh ingredients to customers in a safe, efficient and cost-effective manner. At the same time, the Group plans to replicate its successful experience in the local market in the Greater Bay Area market and also identify potential business partners and explore opportunities in this new market to expedite its development, by working with leading partners and efficiently sharing resources, in hopes of grasping the huge demand of the Greater Bay Area market and expanding income source.In addition, the Group will actively grow its downstream business, including retail- and catering- related business. The Group strives to seize the business opportunities of the retail and catering industry in the Greater Bay Area, further expanding its restaurant network to other cities and its catering business territory in the Greater Bay Area. Leveraging its advantages of the having a whole-industry supply chain that includes upstream, midstream and downstream businesses, the Group will open more restaurants featuring fresh ingredients and gradually establish its food and beverage brand "Wantian Catering". Recently, the Group has strategically opened two restaurants named "Hong Kong Style Seafood Hot Pot Restaurant" and "Korean Seafood BBQ Restaurant" featuring fresh ingredients in Zhongshan city, Guangdong Province. The Group will actively enhance its brand recognition in the Greater Bay Area to expand its customer base and market share.In environmental protection and technology business, the Group actively supports the national development approach of "modern agricultural technology and environmental protection", integrating agricultural technology and green environmental protection, utilising available rooftop for farming and increasing the urban green area. This enables the Group to promote the idea of green city with the supplies of "safe vegetables", and also promote the concept of green education to enterprises and schools in the Greater Bay Area, thus supporting the region's sustainable development.The Group will continue to adopt its multi-pronged approach to accelerate the business development in the Greater Bay Area. Subsequent to the establishment of its headquarters in the Greater Bay Area, the Group officially opened its Zhongshan Branch this month. On 23 June 2022, a grand opening and unveiling ceremony was held in its Zhongshan Branch with the presence of Mr. HOOY Kok Wai, Chairman of the Board and Executive Director; and Mr. ZHONG Xueyong, Chief Executive Officer and Executive Director of China Wantian. The establishment of Zhongshan Branch signifies that Zhongshan, Guangdong province will become the Group's regional headquarters in the Zhuhai-Zhongshan-Jiangmen Economic Circle. The Group is also optimistic about the business prospects of Zhongshan, Guangdong Province, striving to embark its three main businesses from Zhongshan, Guangdong Province and gradually expand its businesses to the Greater Bay Area market.Looking ahead, following the phased easing of social gathering restrictions by Hong Kong government, the catering business environment has improved significantly. The Group expects its business in the city to develop steadily. At the same time, the role of Group's Hong Kong headquarters as a financial centre can provide full support as a strong backing to its Shenzhen headquarters. As the Chinese economy is expected to recover rapidly in the post-pandemic era, the Group's Greater Bay Area business will become increasingly important. In the long run, the business in the Greater Bay Area is expected to bring stable and sustainable income to the Group and poised to become the key growth engine for the Group's business. The Group officially changed its Chinese and English name respectively to "China Wantian Holdings Limited" in December 2021, manifesting its adjustment in business strategies and proactive rejuvenation of corporate image, which fosters the future business development of the Group.The Group's management expressed that the Greater Bay Area, being one of China's most open and economically vital regions, is of great importance for the nation's continued development. With its huge market, unique regional advantages, open trade environment and dynamic industry structure, the Greater Bay Area will create unprecedented development opportunities for the Group. The establishment of the Group's Shenzhen headquarters is the first part of its business development strategy for the Greater Bay Area. In the future, the Group will focus on developing three main businesses in this market, including fresh food supply, retail and catering, as well as environmental protection and technology. The Group will establish a whole-industry supply chain that includes upstream, midstream and downstream businesses in the Greater Bay Area, and boost its market share by leveraging its unique competitive advantages. The management believe that the three main business initiatives, with their strong synergies, will open up unique opportunities and facilitate the establishment of a leading green brand in the Greater Bay Area.About China Wantian Holdings LimitedChina Wantian (1854.HK) is principally engaged in sourcing, processing and supplying food ingredients, with a focus on the provision of vegetables and fruit to food service operators in Hong Kong. It supplies in excess of 1,300 food ingredients to more than 480 customers. In May 2022, China Wantian established its Greater Bay Area headquarters in Shenzhen, marking its official debut in the Greater Bay Area market. The Group will focus on developing three main businesses in this market, including fresh food supply, retail and catering, as well as environmental protection and technology and actively establish a leading green brand in the Greater Bay Area to provide customers with fresh, healthy and safe food.For more details, please visit: chinawantian.etnet.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
AEON Credit (00900) 1Q2022 Revenue up by 9.7% to HK$279.1 million ACN Newswire

AEON Credit (00900) 1Q2022 Revenue up by 9.7% to HK$279.1 million

HONG KONG, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - AEON Credit Service (Asia) Company Limited ("AEON Credit" or the "Group"; Stock Code: 00900) today announced its unaudited results for the three months ended 31 May 2022 ("1Q2022", or the "reporting period"). For 1Q2022, the Group's revenue increased 9.7% year-on-year to HK$279.1 million and operating profit before impairment losses and impairment allowances was up by 16.4% to HK$126.9 million. The Group recorded profit of HK$82.7 million (1Q2021: HK$97.0 million) and earnings per share of 19.74 HK cents for the reporting period.Overall sales for 1Q2022 increased by 12.3% against 1Q2021, with gross advances and receivables balance up by 4.0% relative to the amount at end of February 2022. With an increase in sales for the Group, both as a credit card issuer and acquirer and an insurance intermediary, the Group recorded a year-on-year increase of HK$7.4 million in fees and commissions, reaching a total of HK$28.9 million. Interest income, meanwhile, increased by HK$15.8 million to HK$233.9 million, driven by the continued rise in receivable balances. These, combined with the increase in handling and late charges due to the rising demand in cash advance, led to the robust growth in the Group's revenue and operating profit. However, the expectation of slow economic recovery in the reporting period in stark contrast with the expected rebound in key economic indicators in 1Q2021, resulted in a relatively significant increase in impairment losses and impairment allowances in 1Q2022, which led to the decline in profit during the reporting period, despite the solid top-line growth.As part of its strategy to cater for the shift in customer spending towards the Internet under the new normal and expand its customer base, the Group launched its first ever cashback credit card, AEON Card Wakuwaku (the "Wakuwaku card"), in May 2022, which allows cardholders to enjoy special spending rebates for online and overseas spending in Japan. Supported by celebrity endorsement to attract a younger generation of customers, it has received a favourable response with more than 5,000 Wakuwaku cards issued in the first month of its debut.Following its successful marketing and brand building efforts for the Wakuwaku card, the Group will place yet more emphasis on using both digital and traditional marketing channels to promote its credit card and personal loan products and to roll out different marketing programmes to enrich customers' user experience. Regarding its technology development endeavours, AEON Credit's card and loan system replacement project is targeted to be completed towards the end of the current financial year, after which the Group will be able to launch new payment solutions, enjoy flexibility in offering product benefits and have access to even better data analysis tools. With a strong capital position, the Group will continue to dedicate resources to the expansion of its branch network, providing higher quality customer experiences, accelerating digitalisation and exploring new investment opportunities to expand and diversify its businesses.Mr. Tomoharu Fukayama, Managing Director of AEON Credit said, "The Group is glad to have achieved positive revenue and operating profit growth in 1Q2022 despite the challenging operating environment amid the fifth wave of the Pandemic. The implementation of our strategy to address the shift in customer spending behaviour and appeal to the younger generation has made good progress with the successful launch of our Wakuwaku card. To embrace changing customer needs and capture the arising market opportunities, we will also continue to ramp up our marketing and promotions using a variety of channels and increase our technology upgrade and digitalisation efforts."About AEON Credit Service (Asia) Company Limited (Stock Code: 00900)AEON Credit Service (Asia) Company Limited, a subsidiary of AEON Financial Service Co., Ltd. (TSE: 8570) and a member of the AEON Group, was set up in 1987 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 1995. The Group is principally engaged in the consumer finance business, which includes the issuance of credit cards and the provision of personal loan financing, card payment processing services, insurance agency and brokerage business in Hong Kong and microfinance business in Mainland China.For more information, please visit the company's website at www.aeon.com.hk. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
EC Healthcare Announces FY2021/22 Annual Results ACN Newswire

EC Healthcare Announces FY2021/22 Annual Results

HONG KONG, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong, announces today its audited annual results for the fiscal year ended 31 March 2022 (the "Year").Business Highlight -- Sales volume achieved record high of HK$3,122.3 million, up 40.7% YoY-- Total revenue surged 40.3% YoY to a record high of HK$2,919.5 million-- Revenue from medical services segment increased significantly by 64.6% YoY to a record high of HK$1,689.0 million, boosting its revenue contribution to 57.9%-- Earnings before interest, taxes, depreciation, and amortization ("EBITDA") increased by 35.0% YoY to a record high of HK$536.4 million-- Net profit after tax for the Year was HK$270.5 million, increased by 19.9% YoY, basic earnings per share was 17.1 HK cents-- The board of directors (the "Board") proposed final cash dividend of 4.2 HK cents per share, which together with the interim dividend of 10.2 HK cents per share, will bring the total annual dividend to 14.4 HK cents per share, representing an annual dividend payout ratio of 84.2%-- As at 31 March 2022, the total valuation of the Group's M&A transactions completed was HK$641.1 million, spanning across veterinary, dental, and various medical specialties, which further strengthened the Group's medical services layout -- The Group's suite of medical services extends to 29 specialist disciplines, and the number of full-time and exclusive registered practitioners has increased to 251-- Total number of service points increased to 147, total gross floor area increased by 34.2% YoY to approximately 534,000 sq. ft-- The Group has been committed to its social responsibility during the COVID-19 pandemic by deploying resources to provide a wide range of anti-pandemic services, aiding the joint fight against the virus-- The Group maintained the leading role as the largest medical service provider (non-hospital) in Hong Kong in terms of revenue in 2021, according to Frost and SullivanDuring the Year, the Group's businesses demonstrated strong resilience to grow continually amidst a challenging operating environment caused by the fifth wave of the COVID-19 outbreak in Hong Kong, and further consolidated its leading position in the industry. The Group posted a record high sales volume of HK$3,122.3 million, up 40.7% year-on-year ("YoY"), while revenue also surged by 40.3% YoY to a record high of HK$2,919.5 million. Organic revenue increased by 49.8% YoY to HK$2,761.4 million, accounting for 94.6% of the total, thanks to the Group's long-term investments in technology, service, branding, corporate culture, and its flexible and effective operations management. During the Year, medical segment continued to be the key growth driver as medical revenue marked record high and increased significantly by 64.6% YoY to HK$1,689.0 million. The Group's EBITDA (earnings before interest, taxes, depreciation, and amortization) increased by 35.0% YoY to a record high HK$536.4 million. The Group's net profit after tax for the Year increased 19.9% YoY to HK$270.5 million, however net profit margin is under pressure of the suspension of the Group's beauty and wellness businesses in Hong Kong for a total of 104 days (total 84 days during the Year) in compliance with government pandemic control measures.The net profit attributable to equity shareholders of the Company increased by 2.4% YoY to HK$197.5 million. Basic earnings per share was 17.1 HK cents, compared to 18.8 HK cents for the same period last year. The board of directors proposed a final cash dividend of 4.2 HK cents per share. During the Year, the number of unique customers steadily increased to 182,300 (1) during the Year and the contribution from existing customers accounted for 64.3% (2 )to the Group's total revenue. Customer loyalty remained high with repurchase purchase rate of 90.2% (3). Driven by the synergies created by the Group's enclosed healthcare ecosystem, over 27.5% (4) of its customers have made purchases across its various brands in the Year. Meanwhile, the Group has maintained premium service quality with 99.96% (5) of customers' satisfaction rate. The Group maintained its leading role as the largest medical service provider (non-hospital) in Hong Kong in terms of revenue in 2021, according to Frost and Sullivan.Our number of service points increased through organic expansion and acquisition growth. During the Year, we have ventured into veterinary business and acquired 7 vet clinics and 2 vet advanced imaging centers. As at 31 March, 2022, the Group had total number of service points of 127 in Hong Kong, 4 in Macau and 16 in Mainland China with total gross floor area of approximately 534,000 sq. ft. Out of the net increase of approximately 136,000 sq. ft. floor area in FY2022, 71.9% came from the medical business and 28.1% from the aesthetic medical and beauty and wellness services business.Strong growth in medical segmentFor medical business, demand for the Group's medical services remained strong in FY2022. The Group continued to grow its market share through both organic and M&A growth strategies. Revenue from the Group's medical services segment increased significantly by 64.6% YoY to a record high HK$1,689.0 million, boosting its revenue contribution to 57.9%, of which organic expansion and M&A completed during FY22 accounted for 95.0% and 5.0% respectively. Organic growth is driven by surged demand for COVID-19 related services and rising healthcare sentiment. During FY22, the total valuation of acquisitions completed in medical segment was HK$460.7 million, spanning dental and various medical specialties. The Group's suite of medical services spans 29 specialist disciplines, and our headcount of full-time and exclusive registered practitioners has increased to 251.Resilient result from aesthetic medical and beauty and wellness services segmentFor aesthetic medical and beauty and wellness business, the Group demonstrated its resilience by achieving steady growth, thanks to the brand capital established over the years. During the Year, revenue contributed by aesthetic medical and beauty and wellness services increased by 10.2% YoY to HK$1,091.2 million. Revenue from Hong Kong remains stable at HK$804.7 million. Revenue from Mainland China increased by 28.4% YoY to HK$173.2 million, while revenue from Macau, China surged 119.6% YoY to HK$113.4 million due to a strong recovery of medical tourism.Embracing social responsibility by stepping up our response in the community during COVID-19As Hong Kong's leading private healthcare service provider, the Group stepped up during the COVID-19 pandemic to provide a wide range of anti-pandemic measures to the public. For example, we offered telemedicine and drug delivery services through our clinics as well as government-approved nucleic acid tests (RT-PCR) and antibody tests through our accredited laboratories. The Group also provides COVID-19 vaccinations to the public and has joined hands with charitable organizations to donate rapid test kits to those in need.Set up 2030 sustainability goals To assimilate sustainability into our business, the Group has taken a proactive approach to set up a sustainability working group with board of directors' oversight to execute our sustainability strategy. We have conducted stakeholder engagement surveys and set up our 2030 sustainability goals based on the findings. Operation & IT-related risks atop our stakeholders' concerns, we will further advance our operation protocols and have engaged third party consultant to review our data governance policy. Latest Business Developments after the Reporting PeriodAfter the annual reporting period, the Group has announced the acquisitions of two new medical businesses and formed one joint ventures, which will further expand the market share of the Group's medical business and extend the scope of the Group's medical services and its business presence.On 7 April 2022, the Group announced to acquire 75% of the issued share capital of a veterinary hospital in Tai Po for a total consideration of HK$15.75 million in cash. Upon completion, the Group will operate a total of 8 veterinary hospital, 2 veterinary imaging centers in Hong Kong.On 23 May 2022, the Group announced to acquire 75% of the issued share capital of Mobile Medical International Holdings Limited and its subsidiaries for a total consideration of HK$41.25 million in cash. Upon completion, the Group will operate a total of 6 health screening services centers, covering New Territories, Kowloon and Hong Kong Island, thereby further consolidating the health screening market in Hong Kong.On 6 June 2022, the Group announced to spearhead an unprecedented medical tenant - landlord collaboration and formed a joint venture with a real estate investment management company, KaiLong Group and Asia Allied Infrastructure Holdings Limited to co-build a premium purpose-built medical grade building in Hong Kong. The Group will be the anchor tenant of this Medical Building upon completion. The Group has conditionally agreed to make initial capital contributions to the joint venture company of up to HK$275 million, which will represent 30% of the total enlarged issued share capital of the joint venture company.On 21 June 2022, the Group signed its first sustainability-linked facility ("SLL Facility") totaling HK$ 700 million. This inaugural dual-tranche SLL Facility is a first-of-its-kind for a healthcare services provider in Hong Kong, complementing the Group's established status as a leading industry pioneer and reaffirms the importance of sustainability in the Group's future growth strategy. Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group believes the medical market will remain relatively resilient under the challenging environment and public-private partnership will continue to increase Hong Kong's private medical spending in the long run. Looking forward, the Group we will diversify within medical and beauty sectors, which allow us to further increase in service offerings to our customers to better meet their needs. We will also continue to expand our strategic partnerships with key players in technology, telecom, property, insurance and pharmaceutical industries to form our healthcare ecosystem. The Group committed to uphold sustainability principles. Moving forward, we will excel through our sustainability journey together with our much-valued stakeholders. We will also be proactive in continuously refining our strategies for the overall welfare of our company and the greater community."About EC Healthcare EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, a advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 20211. Based on revenue for the year2. Revenue contribution by existing customers to the total revenue for the year3. Customers of FY21 contribution in FY22 divided by the total revenue in FY214. Number of customers who purchased services from more than one brand for the year divided by total number of customers for the year 5. 100% minus the percentage of material unfavourable feedback of total revenue for the yearFor further information, please contact: iPR Ogilvy Limited Callis Lau / Lorraine Luk / Charmaine Ip Tel: (852) 2136 6952 / 2169 0467 / 3920 7649 Fax: (852) 3170 6606 Email: ech@iprogilvy.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SEAPRWire宣布在东南亚地区的新闻稿媒体网络重大拓展 SeaPRwire

SEAPRWire宣布在东南亚地区的新闻稿媒体网络重大拓展

Singapore - 作为其新闻稿媒体投放网络重大扩展的一部分,新闻稿分发服务提供商 SEAPRWire 宣布进一步扩展其在新加坡、越南、菲律宾、泰国和香港的媒体网络。 通过一系列战略合作伙伴关系和媒体联盟,SEAPRWire 现在为客户的每一篇新闻稿提供 60 多个东南亚地区媒体展示。这个数字已经使SEAPRWire成为东南亚地区最大的媒体网络分发服务机构之一。 拓展后的SEAPRWire媒体网络达到60多家媒体;服务区域覆盖东盟10国及香港;支持的语言包括:英语、繁体中文、简体中文、马来语、印度尼西亚语、越南语、泰语、菲律宾语等。新增的媒体包括: 大中华地区6家媒体(简体中文、繁体中文、英文):com, EastMud.com, NetDace.com, AsiaFeatured.com, AseanFun.com, AseanTrend.com 新加坡3家媒体(简体中文、英文):com, VOASG.com, TodayInSG.com 香港3家媒体(繁体中文,英文):com, TIHongKong.com, DirHongKong.com 菲律宾3家媒体(菲律宾语、英文):com, EventPH.com, PHNewLook.com 越南3家媒体(越南语、英文):com, PostVN.com, VietnamClipping.com 泰国3家媒体(泰文、英文):com, InsightTH.com, ThaiLandLatest.com “对于公关专业人士、营销人员、小企业和组织,他们试图通过东南亚媒体和KOL以报道他们的新闻事件。而传统的媒体服务并没有为他们提供强大的本地影响力、成本效益或对市场的细致入微的了解,”SEAPRWire首席营销官YQ Tang表示,“SEAPRWire 专注于东南亚市场,我们增加了新的合作伙伴,并且积极拥抱社交网络多媒体,使SEAPRWire成为一个强大的价值平台,以提高知名度。” 2022年5 月,SEAPRWire 和 EQS Group (www.eqs.com) 宣布在亚洲(东亚和东南亚)建立媒体合作伙伴关系。合作内容包括媒体名单扩展和媒体外展业务合作。合作范围涵盖中国大陆、香港、新加坡、泰国、越南、马来西亚、印度尼西亚和菲律宾。双方期待未来进一步合作。 “这是一个战略联盟,将加强亚洲多语种媒体内容的质量和分发,”YQ Tang说。 关于SEAPRWire SEAPRWire (https://www.seaprwire.com/)是东南亚具有影响力的金融和商业新闻社,深受亚洲机构投资者和金融科技平台的信赖。该平台可识别交易和投资机会并建立良好的投资者体验。它在东南亚地区具有强大的媒体网络,索引来自全球数千个来源的新闻。SEAPRWire 的媒体网络支持多语种新闻稿发布,包括英语、繁体中文、简体中文、越南语、泰语、马来语、印度尼西亚语、菲律宾语等。 For media inquiry: Tina Lee, SEAPRWire cs@seaprwire.com https://seaprwire.com
More

Allerton Busan Group Releases Financial Report on Euronext New Tech Leaders Index

TORONTO, Ontario, June 16, 2022 – (SEAPRWire) – Allerton Busan Group has today issued a financial report on the significant importance for Euronext as they established a new technology segment – Euronext Tech Leaders – to help the sector’s leading companies gain greater visibility among asset managers and other investors across the continent. John Field, Senior Vice President at Allerton Busan Group, said of the announcement, “The European NASDAQ of high tech companies has finally arrived, and both our brokers and investors are equally enthusiastic. Euronext Tech Leaders will help EU firms grow at levels similar to that of US tech giants.” Around one hundred firms have been selected in the seven markets of presence (Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo, and Paris). The first companies chosen must, as a rule, have a market capitalization above €300 million and a minimum growth rate to be included, with no performance criteria for those with a market capitalization of more than 1 billion euros, according to intelligence gathered by Allerton Busan Group. Euronext has revealed the new segment will also offer pre-listing services to assist privately-held high-growth firms in listing publicly by providing advisory services and executive training. Europe has long aspired to produce ‘homegrown’ tech giants to compete with Nasdaq, often the preferred stock exchange for global tech listings. “Euronext Tech Leaders will not compete with Nasdaq. Moreover, it is seeking to develop a fundamentally different approach with the aim to defragment tech listings spread across national markets to give them a European profile and offer a sector-wide view to investors,” said Andrew Stanford, Executive Director of Corporate Equities at Allerton Busan Group. Neuer Markt, a unique tech segment on Deutsche Boerse in Frankfurt, was established in 1997 as Europe’s answer to Nasdaq but the dot-com bubble burst just five years later, and the market collapsed. Efforts by the European Union to deepen its capital market have intensified after the United Kingdom left the EU and started to draw more listings to its London Exchange in effort to compete with the Amsterdam exchange run by Euronext. “Today, the European tech ecosystem is alive and kicking, with a growing number of pioneering SMEs and an ever-expanding community of investors emerging from investment firms just like our own. We are excited to see how the Euronext Tech Leaders segment will further fuel the growth of this booming tech sector,” added George Baxter, who currently heads up Institutional Trading at Allerton Busan Group. About Allerton Busan Group Allerton Busan Group is a financial services company committed to managing clients’ finances and creating an environment where clients, clients’ business, and clients’ family can thrive both now and in the future. Media Relations Company: Allerton Busan group Contact: Austin Arnold Email: austin.arnold@abg-management.com Phone: +1 437 837 1110 Website: https://www.abg-management.com/ SOURCE: Allerton Busan Group The article is provided by a third-party content provider. SEAPRWire ( www.seaprwire.com ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Indonesia, Thailand, Vietnam, Singapore, Malaysia, Philippines & Hong Kong )
More

友和集团控股有限公司宣布联交所主板上市计划

EQS 新闻 via SEAPRWire.com / 2022-05-25 / 18:38 UTC+8 Yoho Group Holdings Limited 友和集团控股有限公司 (于开曼群岛注册成立的有限公司) (股份代号:2347.HK) 友和集团控股有限公司宣布联交所主板上市计划 每股作价2.10至2.60港元 上市所得款预计为约129.3百万港元 [香港-2022年5月25日] 香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一友和集团控股有限公司(「友和集团」或「本公司」,连同其附属公司,统称 「本集团」,股份代号:2347.HK)今天宣布其于香港联合交易所有限公司(「联交所」)主板上市之计划。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。按20/21 财年的网站流量及整体零售业网上销售计,本集团亦于香港所有电子商务平台中分别排名第二及第三(市场占有率约为1.8%)。 本集团计划发售55,000,000股股份(可予重新分配及视乎超额配股权行使与否而定 ) (「发售股分」),其中5,500,000股股份将用作香港公开发售股份(可予重新分配),其余49,500,000股公开发售之股份将用作国际配售(可予重新分配及视乎超额配股权行使情况而定),每股发售价介乎2.10港元至2.60港元(「发售价」)。本公司将于2022年5月26日(星期四)上午九时正起公开招股,至2022年5月31日(星期二)中午十二时正截止。本公司股份预期将于2022年6月10日(星期五)开始于联交所主板进行买卖,股份代号为2347.HK,股份的买卖单位将为每手2,000股。 民银资本有限公司为独家保荐人;永时证券有限公司为财务顾问;民银证券有限公司独家全球协调人、联席账簿管理人及联席牵头经办人;艾德证券期货有限公司、海通国际证券有限公司、中泰国际证券有限公司、中国光大证券(香港)有限公司、软库中华金融服务有限公司、中国通海证券有限公司、富途证券国际(香港)有限公司、华盛资本证券有限公司及信达国际融资有限公司为其他联席账簿管理人及其他联席牵头经办人;长雄证券有限公司、中天证券有限公司、越秀证券有限公司、富德金融有限公司及利弗莫尔证券有限公司是其他联席牵头经办人。 友和集团控股有限公司采用在线线下融合(OMO)模式的零售业务,包括以下B2C模式下的零售销售渠道:(i) 透过友和电子商务平台(包括桌上计算机版及流动版)进行网上B2C销售;(ii) 透过奖赏计划平台及第三方在线平台向终端客户进行网上B2B2C销售;及(iii)在两间零售店(即观塘店及长沙湾旗舰店)进行线下B2C销售。于发放这份新闻稿前的最后可行日期(「最后可行日期」),本集团的产品组合种类繁多,涵盖逾23,000项SKU,可划分为以下五个类别:电子产品、美容及护理电子产品、家庭电器、计算机及计算机外设产品及生活时尚产品。 本集团的供货商主要为亚洲品牌拥有人、授权分销商及贸易公司等。凭借友和OMO业务多年来的迅速发展,本集团于截至2021年3月31日止三个财政年度及截至2021年11月30日止八个月(「往绩记录期间」)已与逾590 名供货商建立稳固的业务关系网络,可直接与若干顶尖品牌接洽,并获得若干产品在香港的分销权。因此,本集团能以优惠价格采购各式各样的优质正货。本集团的五大供货商分别占18/19财年、19/20财年、20/21财及21/22首八个月年采购总额约37.6%、30.1%、25.1% 及24.9%,而本集团的最大供货商于各期间占采购总额12.8%、9.7%、6.5% 及6.6%。 于18/19财年、19/20 财年、20/21 财年及21/22 首八个月,本集团的总收益分别约为135.4 百万港元、260.0百万港元、523.0百万港元及496.7百万港元;同期本集团的经调整纯利则分别约为13.0百万港元、17.6百万港元、28.7百万港元及13.6百万港元。 本集团在营运规模、财务表现及市场占有率方面取得可观增长,相信其拥有以下竞争优势维持市场地位及促进未来发展: 香港B2C电子商务行业的顶尖市场参与者之一,享誉盛名、拥有良好口碑及庞大客户群 自有完善的友和电子商务平台引以自豪 致力追求创新并善用科技的力量 凭借对本地市场的洞悉力,采取多方位的市场推广及促销策略 管理团队勤勉敬业、卓有远见且富进取精神 以发售价每股发售股份2.35港元(即本招股章程所列发售价范围的中位数)计算,本集团预期全球发售所得款项约为129.3百万港元。经扣除包销费用及佣金以及与全球发售有关的估计应付开支,本集团计划将全球发售所得款项净额约87.9百万港元用于以下用途: 约20.4%或17.9百万港元预期将用于透过自然增长抢占更高市场占有率; 约7.1%或6.2百万港元预期将用于透过推出线上平台业务扩大电子商务平台的产品供应种类; 约8.6%或7.6百万港元预期将用于服务拓展至中国(尤其是大湾区)客户; 约9.2%或8.1百万港元预期将用于加强供应链能力; 约11.8%或10.4百万港元预期将用于进一步投资于品牌管理及市场推广,提高公众对本集团的认识及加强市场推广活动的成效; 约19.2%或16.9百万港元预期将用于扩大员工队伍以支持业务策略; 约13.7%或12.0百万港元预期将用于收购电子商务相关行业的公司;及 约10.0%或8.8百万港元将用于一般营运资金 - 完 - 友和集团控股有限公司 友和集团控股有限公司为香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一,采用OMO模式的零售业务。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。 此新闻稿由金通策略代表友和集团控股有限公司发放。 如有任何查询,请联络: DLK Advisory 金通策略 电话: +852 2857 7101 传真: +852 2857 7103 文件: 友和集团控股有限公司宣布联交所主板上市计划 2022-05-25 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php EQS 新闻 via SEAPRWire.com / 2022-05-25 / 18:38 UTC+8 Yoho Group Holdings Limited 友和集团控股有限公司 (于开曼群岛注册成立的有限公司) (股份代号:2347.HK) 友和集团控股有限公司宣布联交所主板上市计划 每股作价2.10至2.60港元 上市所得款预计为约129.3百万港元 [香港-2022年5月25日] 香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一友和集团控股有限公司(「友和集团」或「本公司」,连同其附属公司,统称 「本集团」,股份代号:2347.HK)今天宣布其于香港联合交易所有限公司(「联交所」)主板上市之计划。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。按20/21 财年的网站流量及整体零售业网上销售计,本集团亦于香港所有电子商务平台中分别排名第二及第三(市场占有率约为1.8%)。 本集团计划发售55,000,000股股份(可予重新分配及视乎超额配股权行使与否而定 ) (「发售股分」),其中5,500,000股股份将用作香港公开发售股份(可予重新分配),其余49,500,000股公开发售之股份将用作国际配售(可予重新分配及视乎超额配股权行使情况而定),每股发售价介乎2.10港元至2.60港元(「发售价」)。本公司将于2022年5月26日(星期四)上午九时正起公开招股,至2022年5月31日(星期二)中午十二时正截止。本公司股份预期将于2022年6月10日(星期五)开始于联交所主板进行买卖,股份代号为2347.HK,股份的买卖单位将为每手2,000股。 民银资本有限公司为独家保荐人;永时证券有限公司为财务顾问;民银证券有限公司独家全球协调人、联席账簿管理人及联席牵头经办人;艾德证券期货有限公司、海通国际证券有限公司、中泰国际证券有限公司、中国光大证券(香港)有限公司、软库中华金融服务有限公司、中国通海证券有限公司、富途证券国际(香港)有限公司、华盛资本证券有限公司及信达国际融资有限公司为其他联席账簿管理人及其他联席牵头经办人;长雄证券有限公司、中天证券有限公司、越秀证券有限公司、富德金融有限公司及利弗莫尔证券有限公司是其他联席牵头经办人。 友和集团控股有限公司采用在线线下融合(OMO)模式的零售业务,包括以下B2C模式下的零售销售渠道:(i) 透过友和电子商务平台(包括桌上计算机版及流动版)进行网上B2C销售;(ii) 透过奖赏计划平台及第三方在线平台向终端客户进行网上B2B2C销售;及(iii)在两间零售店(即观塘店及长沙湾旗舰店)进行线下B2C销售。于发放这份新闻稿前的最后可行日期(「最后可行日期」),本集团的产品组合种类繁多,涵盖逾23,000项SKU,可划分为以下五个类别:电子产品、美容及护理电子产品、家庭电器、计算机及计算机外设产品及生活时尚产品。 本集团的供货商主要为亚洲品牌拥有人、授权分销商及贸易公司等。凭借友和OMO业务多年来的迅速发展,本集团于截至2021年3月31日止三个财政年度及截至2021年11月30日止八个月(「往绩记录期间」)已与逾590 名供货商建立稳固的业务关系网络,可直接与若干顶尖品牌接洽,并获得若干产品在香港的分销权。因此,本集团能以优惠价格采购各式各样的优质正货。本集团的五大供货商分别占18/19财年、19/20财年、20/21财及21/22首八个月年采购总额约37.6%、30.1%、25.1% 及24.9%,而本集团的最大供货商于各期间占采购总额12.8%、9.7%、6.5% 及6.6%。 于18/19财年、19/20 财年、20/21 财年及21/22 首八个月,本集团的总收益分别约为135.4 百万港元、260.0百万港元、523.0百万港元及496.7百万港元;同期本集团的经调整纯利则分别约为13.0百万港元、17.6百万港元、28.7百万港元及13.6百万港元。 本集团在营运规模、财务表现及市场占有率方面取得可观增长,相信其拥有以下竞争优势维持市场地位及促进未来发展: 香港B2C电子商务行业的顶尖市场参与者之一,享誉盛名、拥有良好口碑及庞大客户群 自有完善的友和电子商务平台引以自豪 致力追求创新并善用科技的力量 凭借对本地市场的洞悉力,采取多方位的市场推广及促销策略 管理团队勤勉敬业、卓有远见且富进取精神 以发售价每股发售股份2.35港元(即本招股章程所列发售价范围的中位数)计算,本集团预期全球发售所得款项约为129.3百万港元。经扣除包销费用及佣金以及与全球发售有关的估计应付开支,本集团计划将全球发售所得款项净额约87.9百万港元用于以下用途: 约20.4%或17.9百万港元预期将用于透过自然增长抢占更高市场占有率; 约7.1%或6.2百万港元预期将用于透过推出线上平台业务扩大电子商务平台的产品供应种类; 约8.6%或7.6百万港元预期将用于服务拓展至中国(尤其是大湾区)客户; 约9.2%或8.1百万港元预期将用于加强供应链能力; 约11.8%或10.4百万港元预期将用于进一步投资于品牌管理及市场推广,提高公众对本集团的认识及加强市场推广活动的成效; 约19.2%或16.9百万港元预期将用于扩大员工队伍以支持业务策略; 约13.7%或12.0百万港元预期将用于收购电子商务相关行业的公司;及 约10.0%或8.8百万港元将用于一般营运资金 - 完 - 友和集团控股有限公司 友和集团控股有限公司为香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一,采用OMO模式的零售业务。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。 此新闻稿由金通策略代表友和集团控股有限公司发放。 如有任何查询,请联络: DLK Advisory 金通策略 电话: +852 2857 7101 传真: +852 2857 7103 文件: 友和集团控股有限公司宣布联交所主板上市计划 2022-05-25 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More

友和集团控股有限公司宣布联交所主板上市计划

EQS 新闻 via SEAPRWire.com / 2022-05-25 / 18:38 UTC+8 Yoho Group Holdings Limited 友和集团控股有限公司 (于开曼群岛注册成立的有限公司) (股份代号:2347.HK) 友和集团控股有限公司宣布联交所主板上市计划 每股作价2.10至2.60港元 上市所得款预计为约129.3百万港元 [香港-2022年5月25日] 香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一友和集团控股有限公司(「友和集团」或「本公司」,连同其附属公司,统称 「本集团」,股份代号:2347.HK)今天宣布其于香港联合交易所有限公司(「联交所」)主板上市之计划。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。按20/21 财年的网站流量及整体零售业网上销售计,本集团亦于香港所有电子商务平台中分别排名第二及第三(市场占有率约为1.8%)。 本集团计划发售55,000,000股股份(可予重新分配及视乎超额配股权行使与否而定 ) (「发售股分」),其中5,500,000股股份将用作香港公开发售股份(可予重新分配),其余49,500,000股公开发售之股份将用作国际配售(可予重新分配及视乎超额配股权行使情况而定),每股发售价介乎2.10港元至2.60港元(「发售价」)。本公司将于2022年5月26日(星期四)上午九时正起公开招股,至2022年5月31日(星期二)中午十二时正截止。本公司股份预期将于2022年6月10日(星期五)开始于联交所主板进行买卖,股份代号为2347.HK,股份的买卖单位将为每手2,000股。 民银资本有限公司为独家保荐人;永时证券有限公司为财务顾问;民银证券有限公司独家全球协调人、联席账簿管理人及联席牵头经办人;艾德证券期货有限公司、海通国际证券有限公司、中泰国际证券有限公司、中国光大证券(香港)有限公司、软库中华金融服务有限公司、中国通海证券有限公司、富途证券国际(香港)有限公司、华盛资本证券有限公司及信达国际融资有限公司为其他联席账簿管理人及其他联席牵头经办人;长雄证券有限公司、中天证券有限公司、越秀证券有限公司、富德金融有限公司及利弗莫尔证券有限公司是其他联席牵头经办人。 友和集团控股有限公司采用在线线下融合(OMO)模式的零售业务,包括以下B2C模式下的零售销售渠道:(i) 透过友和电子商务平台(包括桌上计算机版及流动版)进行网上B2C销售;(ii) 透过奖赏计划平台及第三方在线平台向终端客户进行网上B2B2C销售;及(iii)在两间零售店(即观塘店及长沙湾旗舰店)进行线下B2C销售。于发放这份新闻稿前的最后可行日期(「最后可行日期」),本集团的产品组合种类繁多,涵盖逾23,000项SKU,可划分为以下五个类别:电子产品、美容及护理电子产品、家庭电器、计算机及计算机外设产品及生活时尚产品。 本集团的供货商主要为亚洲品牌拥有人、授权分销商及贸易公司等。凭借友和OMO业务多年来的迅速发展,本集团于截至2021年3月31日止三个财政年度及截至2021年11月30日止八个月(「往绩记录期间」)已与逾590 名供货商建立稳固的业务关系网络,可直接与若干顶尖品牌接洽,并获得若干产品在香港的分销权。因此,本集团能以优惠价格采购各式各样的优质正货。本集团的五大供货商分别占18/19财年、19/20财年、20/21财及21/22首八个月年采购总额约37.6%、30.1%、25.1% 及24.9%,而本集团的最大供货商于各期间占采购总额12.8%、9.7%、6.5% 及6.6%。 于18/19财年、19/20 财年、20/21 财年及21/22 首八个月,本集团的总收益分别约为135.4 百万港元、260.0百万港元、523.0百万港元及496.7百万港元;同期本集团的经调整纯利则分别约为13.0百万港元、17.6百万港元、28.7百万港元及13.6百万港元。 本集团在营运规模、财务表现及市场占有率方面取得可观增长,相信其拥有以下竞争优势维持市场地位及促进未来发展: 香港B2C电子商务行业的顶尖市场参与者之一,享誉盛名、拥有良好口碑及庞大客户群 自有完善的友和电子商务平台引以自豪 致力追求创新并善用科技的力量 凭借对本地市场的洞悉力,采取多方位的市场推广及促销策略 管理团队勤勉敬业、卓有远见且富进取精神 以发售价每股发售股份2.35港元(即本招股章程所列发售价范围的中位数)计算,本集团预期全球发售所得款项约为129.3百万港元。经扣除包销费用及佣金以及与全球发售有关的估计应付开支,本集团计划将全球发售所得款项净额约87.9百万港元用于以下用途: 约20.4%或17.9百万港元预期将用于透过自然增长抢占更高市场占有率; 约7.1%或6.2百万港元预期将用于透过推出线上平台业务扩大电子商务平台的产品供应种类; 约8.6%或7.6百万港元预期将用于服务拓展至中国(尤其是大湾区)客户; 约9.2%或8.1百万港元预期将用于加强供应链能力; 约11.8%或10.4百万港元预期将用于进一步投资于品牌管理及市场推广,提高公众对本集团的认识及加强市场推广活动的成效; 约19.2%或16.9百万港元预期将用于扩大员工队伍以支持业务策略; 约13.7%或12.0百万港元预期将用于收购电子商务相关行业的公司;及 约10.0%或8.8百万港元将用于一般营运资金 - 完 - 友和集团控股有限公司 友和集团控股有限公司为香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一,采用OMO模式的零售业务。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。 此新闻稿由金通策略代表友和集团控股有限公司发放。 如有任何查询,请联络: DLK Advisory 金通策略 电话: +852 2857 7101 传真: +852 2857 7103 文件: 友和集团控股有限公司宣布联交所主板上市计划 2022-05-25 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php EQS 新闻 via SEAPRWire.com / 2022-05-25 / 18:38 UTC+8 Yoho Group Holdings Limited 友和集团控股有限公司 (于开曼群岛注册成立的有限公司) (股份代号:2347.HK) 友和集团控股有限公司宣布联交所主板上市计划 每股作价2.10至2.60港元 上市所得款预计为约129.3百万港元 [香港-2022年5月25日] 香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一友和集团控股有限公司(「友和集团」或「本公司」,连同其附属公司,统称 「本集团」,股份代号:2347.HK)今天宣布其于香港联合交易所有限公司(「联交所」)主板上市之计划。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。按20/21 财年的网站流量及整体零售业网上销售计,本集团亦于香港所有电子商务平台中分别排名第二及第三(市场占有率约为1.8%)。 本集团计划发售55,000,000股股份(可予重新分配及视乎超额配股权行使与否而定 ) (「发售股分」),其中5,500,000股股份将用作香港公开发售股份(可予重新分配),其余49,500,000股公开发售之股份将用作国际配售(可予重新分配及视乎超额配股权行使情况而定),每股发售价介乎2.10港元至2.60港元(「发售价」)。本公司将于2022年5月26日(星期四)上午九时正起公开招股,至2022年5月31日(星期二)中午十二时正截止。本公司股份预期将于2022年6月10日(星期五)开始于联交所主板进行买卖,股份代号为2347.HK,股份的买卖单位将为每手2,000股。 民银资本有限公司为独家保荐人;永时证券有限公司为财务顾问;民银证券有限公司独家全球协调人、联席账簿管理人及联席牵头经办人;艾德证券期货有限公司、海通国际证券有限公司、中泰国际证券有限公司、中国光大证券(香港)有限公司、软库中华金融服务有限公司、中国通海证券有限公司、富途证券国际(香港)有限公司、华盛资本证券有限公司及信达国际融资有限公司为其他联席账簿管理人及其他联席牵头经办人;长雄证券有限公司、中天证券有限公司、越秀证券有限公司、富德金融有限公司及利弗莫尔证券有限公司是其他联席牵头经办人。 友和集团控股有限公司采用在线线下融合(OMO)模式的零售业务,包括以下B2C模式下的零售销售渠道:(i) 透过友和电子商务平台(包括桌上计算机版及流动版)进行网上B2C销售;(ii) 透过奖赏计划平台及第三方在线平台向终端客户进行网上B2B2C销售;及(iii)在两间零售店(即观塘店及长沙湾旗舰店)进行线下B2C销售。于发放这份新闻稿前的最后可行日期(「最后可行日期」),本集团的产品组合种类繁多,涵盖逾23,000项SKU,可划分为以下五个类别:电子产品、美容及护理电子产品、家庭电器、计算机及计算机外设产品及生活时尚产品。 本集团的供货商主要为亚洲品牌拥有人、授权分销商及贸易公司等。凭借友和OMO业务多年来的迅速发展,本集团于截至2021年3月31日止三个财政年度及截至2021年11月30日止八个月(「往绩记录期间」)已与逾590 名供货商建立稳固的业务关系网络,可直接与若干顶尖品牌接洽,并获得若干产品在香港的分销权。因此,本集团能以优惠价格采购各式各样的优质正货。本集团的五大供货商分别占18/19财年、19/20财年、20/21财及21/22首八个月年采购总额约37.6%、30.1%、25.1% 及24.9%,而本集团的最大供货商于各期间占采购总额12.8%、9.7%、6.5% 及6.6%。 于18/19财年、19/20 财年、20/21 财年及21/22 首八个月,本集团的总收益分别约为135.4 百万港元、260.0百万港元、523.0百万港元及496.7百万港元;同期本集团的经调整纯利则分别约为13.0百万港元、17.6百万港元、28.7百万港元及13.6百万港元。 本集团在营运规模、财务表现及市场占有率方面取得可观增长,相信其拥有以下竞争优势维持市场地位及促进未来发展: 香港B2C电子商务行业的顶尖市场参与者之一,享誉盛名、拥有良好口碑及庞大客户群 自有完善的友和电子商务平台引以自豪 致力追求创新并善用科技的力量 凭借对本地市场的洞悉力,采取多方位的市场推广及促销策略 管理团队勤勉敬业、卓有远见且富进取精神 以发售价每股发售股份2.35港元(即本招股章程所列发售价范围的中位数)计算,本集团预期全球发售所得款项约为129.3百万港元。经扣除包销费用及佣金以及与全球发售有关的估计应付开支,本集团计划将全球发售所得款项净额约87.9百万港元用于以下用途: 约20.4%或17.9百万港元预期将用于透过自然增长抢占更高市场占有率; 约7.1%或6.2百万港元预期将用于透过推出线上平台业务扩大电子商务平台的产品供应种类; 约8.6%或7.6百万港元预期将用于服务拓展至中国(尤其是大湾区)客户; 约9.2%或8.1百万港元预期将用于加强供应链能力; 约11.8%或10.4百万港元预期将用于进一步投资于品牌管理及市场推广,提高公众对本集团的认识及加强市场推广活动的成效; 约19.2%或16.9百万港元预期将用于扩大员工队伍以支持业务策略; 约13.7%或12.0百万港元预期将用于收购电子商务相关行业的公司;及 约10.0%或8.8百万港元将用于一般营运资金 - 完 - 友和集团控股有限公司 友和集团控股有限公司为香港企业对消费者(B2C)电子商务行业的先行者及领先市场参与者之一,采用OMO模式的零售业务。根据弗若斯特沙利文报告,于20/21财年,按网站流量计,友和集团于香港以电子产品及家庭电器为主的电子商务平台位列榜首,并在香港所有电子商务平台中录得最高电子产品及家庭电器零售业网上销售,市场占有率约为5.6%。 此新闻稿由金通策略代表友和集团控股有限公司发放。 如有任何查询,请联络: DLK Advisory 金通策略 电话: +852 2857 7101 传真: +852 2857 7103 文件: 友和集团控股有限公司宣布联交所主板上市计划 2022-05-25 此财经新闻稿由EQS Group via SEAPRWire.com转载。本公告内容由发行人全权负责。原文链接: http://www.todayir.com/sc/index.php
More